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 List of abbreviations 
ACPA anti-citrullinated protein/peptide antibodies 
ACR American College of Rheumatology 
AhFibA anti-human fibrinogen antibodies 
AKA anti-keratin antibodies 
ANCA anti-neutrophyl cytoplasmic antibodies 
APF anti-perinuclear factor 
AS ankylosing spondylitis 
ASCA anti-Saccharomyces cerevisiae antibodies 
AUC  area under the curve 
CARD caspase activation and recruitment domain 
CCP cyclic citrullinated peptide 
CD Crohn’s disease 
COR common odds ratio 
DAS disease activity score 
DMARD disease modifying anti-rheumatic drug 
ELISA enzyme linked immunoassay 
ESSG European Spondyloarthropathy Study Group 
HAQ health assessment questionnaire 
HLA-SE HLA-shared epitope 
IBD inflammatory bowel dieseas 
IIF indirect immunofluorescence 
LIA line immunoassay 
MLP multilayered perceptrons 
MDP muramyl dipeptide 
NOD Nuclear oligomerization domain 
NPV negative predictive value 
NSAID non steroidal anti inflammatory drug 
OR odds ratio 
pepA peptide A 
pepB peptide B 
PPV positive predictive value 
PsA psoriatic arthritis 
RA rheumatoid arthritis 
ReA reactive arthritis 
RF rheumatoid factor 
ROC receiver operating characteristics 
SNP Single nucleotide polymorphism 
SpA spondyloarthropathy 
TNF tumor necrosis factor 
UC ulcerative colitis 
uSpA undifferentiated spondyloarthropathy 
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General Introduction 
When a rheumatologist is consulted by a patient with joint complaints, 
the physician attempts to find answers to the following questions: 1) 
What is the diagnosis? 2) What is the present disease activity? 3) What is 
the prognosis? 4) What is the best therapy to lower the present disease 
activity and to ameliorate the prognosis? The answers to those questions 
are formed by a complex composite picture, which is based on clinical 
findings and technical investigations.  
The clinical findings are very important and include the personal and 
familial history, and the clinical examination. Generalisation of these 
findings can be obtained by specific questionnaires and standardized 
clinical measures. Blood tests are available to measure systemic 
inflammation or to search for diagnostic markers, present in different 
rheumatic diseases. Also some genetic tests may be helpful. Imaging 
techniques such as standard X-rays, especially useful to evaluate bone 
damage, provide other important tools. All those measures and markers 
can be seen as variables that, similarly to the hundreds of single 
brushstrokes of a master’s painting, are combined in the physician’s mind 
in order to find the answers to the mentioned questions. Picasso reduced a 
complex drawing of a bull in only 4 lines (front-page). In the present 
work, we will try to find out how a limited number of variables can be 
combined in models for clinical decision-making.  
 
1. Description of the different rheumatic diseases 
One of the most important activities of a rheumatologist is to treat and 
follow-up patients with chronic immune mediated arthritis. These 
encompass rheumatoid arthritis (RA), spondyloarthopathy (SpA), 
psoriatic arthritis (PsA) and arthritis associated with connective tissue 
diseases such as systemic lupus erythematosus (SLE) and systemic 
sclerosis.   
In the present study we will limit the discussion to the most prevalent 
diseases: RA, SpA and PsA. 
 
1.1. Rheumatoid arthritis (RA) 
RA is the best-known immune mediated inflammatory joint disorder and 
affects about 0.3% to 1% of the general population, predominantly 
women [Lawrence 1998, Gabriel 1999, Guillemin 2005]. The disease is 
defined by a symmetric chronic polyarthritis characterised by 
inflammatory pain, morning stiffness and joint swelling. It typically 
affects the small joints of hands and feet (excluding the distal 
interphalangeal joints, more typically affected in PsA). The chronic joint 
inflammation may lead to destruction of cartilage and bone, which is 
radiologically seen by joint space narrowing and marginal erosions. 
Further joint destruction may occur by additional alterations of the 
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tendons and the joint capsule, resulting in deformations of hands and feet 
(Figure 1.1). 
General symptoms such as fatigue and extra-articular manifestations may 
accompany the articular symptoms. Common extra-articular 
manifestations encompass rheumatoid nodules, serositis, hematologic 
manifestations (such as Felty’s syndrome), vasculitis, secondary 
Sjögren’s syndrome and amyloidosis. An important extra-articular 
manifestation, especially useful for diagnostic purposes is the occurrence 
of autoantibodies such as rheumatoid factor (RF) and anti-citrullinated 
protein/peptide antibodies (ACPA). A combination of clinical and 
radiological symptoms and the presence of the rheumatoid factor resulted 
in classification criteria for RA, which are especially useful for study 
purposes (Table 1.1) [Arnett 1988].  
In order to relieve pain and to avoid joint destruction, adequate therapy is 
needed. The therapeutic arsenal for RA encompasses non-steroidal anti-
inflammatory drugs (NSAIDs), disease modifying anti-rheumatic drugs 
(DMARDs) and corticosteroids. NSAIDs control the symptoms of pain or 
stiffness, but they have no effect on the disease progression. Therefore 
they should be combined with DMARDs in order to suppress the local 
joint inflammation and to avoid joint destruction on the long term. 
Among the classical DMARDs, the historically used gold salts and anti-
malarials have been replaced by sulfasalazine, methotrexate, and more 
recently leflunomide. The most frequently used biologicals block tumour 
necrosis factor-α (TNF). TNF blocking can be obtained by the use of a 
soluble TNF-receptor fusion protein (etanercept), a chimeric IgG anti-
TNF-α monoclonal antibody (infliximab) or a recombinant humanized 
IgG monoclonal antibody (adalimumab). Other biologicals block 
interleukin-1 (Anakinra), CD20 (rituximab) or the T-cell co-stimulatory 
pathway (CTLA4-Ig). Finally, corticosteroids are a potent suppressor of 
the inflammatory response with a quick effect on pain and stiffness. Their 
well-known side effects limit their use [O’dell 2004, Olsen 2004, Haque 
2005]. 
 
Figure 1.1: erosions and deformations caused by RA 
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Table 1.1: ACR revised criteria for the classification of RA (1988) 
1. Morning stiffness in and around the joints, lasting at least one 
hour before maximal improvement 
2. Arthritis of three or more joint areas (soft tissue swelling or fluid, 
observed by a physician) 
3. Arthritis of hand joints (proximal interphalangeal, 
metacarpophalangeal, or wrist joints) 
4. Symmetric arthritis 
5. Rheumatoid nodules (observed by a physician) 
6. Serum rheumatoid factor (demonstration of abnormal amounts of 
serum rheumatoid factor by any method for which the result has 
been positive in <5% of normal control subjects). 
7. Radiographic changes on hand or wrist joints (erosions or bony 
decalcification) 
A patient can be classified as having rheumatoid arthritis if at least 4 of 
these criteria are satisfied. 
Item 1 through 4 must be present for at least 6 weeks 
 
1.2. The spondyloarthropathy concept and its relation with 
inflammatory bowel disease  
1.2.1 Spondyloarthropathy 
Spondyloarthropathy (SpA) is a concept that includes different diseases 
with common characteristics such as peripheral arthritis (asymmetrical, 
pauci-articular, and mainly involving the lower limb), spinal 
inflammation (inflammatory back pain, sacroiliitis, spondylitis), 
enthesopathy, extra-articular manifestations (anterior uveitis, gut 
inflammation, skin symptoms), familial aggregation and the association 
with HLA-B27. The disease entities of SpA encompass ankylosing 
spondylitis (AS), reactive arthritis (ReA), arthritis associated with 
inflammatory bowel disease (IBD), some forms of PsA, some forms of 
juvenile chronic arthritis and undifferentiated SpA.  Different 
classification criteria for the SpA subtypes and the SpA concept have 
been described in order to facilitate classification (e.g. for clinical 
studies).  
For the SpA concept, a set of criteria proposed by the European 
Spondyloarthropathy Study Group (ESSG) [Dougados 1991] and the 
Amor criteria are available [Amor 1991] (Table 1.2.1.a and b). For 
reasons of simplicity, the ESSG criteria are more widely used.  For AS 
the Rome [Kellgren 1962] and New York criteria [Bennett 1967] have 
been revised by van der Linden (Modified New York criteria) [van der 
Linden 1984] (Table 1.2.1.c).  
The presence of sacroiliitis is an important criterion in all classification 
sets. Sacroiliitis can be observed on plain radiographs and is generally 
scored using the New York grading system: 0 – normal; 1 – suspicious; 2 
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– localized sclerosis, erosion, joint widening; 3 – diffuse sclerosis, 
erosion, widening; 4 – ankylosis [van der Linden 1984] (Figure1.2.1.a) .  
The prevalence of SpA can be estimated between 0.2% and 0.9% [Saraux 
2005, Braun 1998, Lawrence 1998]. The therapeutic strategies for SpA 
were until recently limited to the use of NSAID, physiotherapy and 
sulfasalazine (for patients with peripheral arthritis).  In analogy with RA, 
treatment with biologicals, such as TNF-α blockers proved also to be very 
effective [Van den Bosch 2002, Anadarajah 2005]. 
 
Table 1.2.1.a: ESSG criteria for spondyloarthropathy (1991) 
Inflammatory spinal pain 
OR 
Synovitis Predominantly of the lower limbs Asymmetric 
AND 
One or more of the following: 
- Positive family history (presence in first-degree or second-degree 
relatives of any of the following: AS, psoriasis, acute uveitis, 
reactive arthritis, inflammatory bowel disease) 
- Psoriasis 
- Inflammatory bowel disease 
- Urethritis, cervicitis, or acute diarrhea within 1 month before 
arthritis 
- Buttock pain alternating between right and left gluteal areas 
- Enthesopathy 
- Sacroiliitis 
 
Table 1.2.1.b: Amor criteria for spondyloarthropathy (1991) 
Clinical symptoms or past history of:  
1. Lumbar dorsal pain at night and/or morning stiffness of lumbar 
or dorsal area 
1 
2. Asymmetric oliogoarthritis 2 
3. Buttock pain (if alternate buttock pain) 1(2) 
4. Dactylitis 2 
5. Heel pain or other well defined enthesopathy 2 
6. Acute anterior uveitis 2 
7. Non-gonococcal urethritis or cervicitis within 1 month before 
onset of arthritis 
1 
8. Acute diarrhea within 1 month before the onset of the arthritis 1 
9. Psoriasis or balanitis or inflammatory bowel disease 2 
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10. Sacroiliitis ≥ grade 2 bilateral , ≥grade 3 if unilateral 2 
11. Presence of HLA-B27 antigen and/or family history of 
ankylosing spondylitis, reactive arthritis, uveitis or inflammatory 
bowel disease 
2 
12. Clear-cut improvement within 48 h after taking NSAID or 
rapid relapse of pain after discontinuation 
2 
Number of points required for the diagnosis of SpA: 6 points  
 
Table 1.2.1.c: Modified New York criteria for AS (1984) 
Diagnosis 
Clinical criteria 
• Low back pain and stiffness for more than 3 months which 
improves with exercise, and is not relieved by rest. 
• Limitation of motion of the lumbar spine in both the sagittal and 
frontal planes. 
• Limitation of chest expansion relative to normal values corrected 
for age and sex 
Radiological criterion 
• Sacroiliitis grade ≥2 bilaterally or sacroiliitis grade 3-4 
unilaterally 
Grading 
Definite ankylosing spondylitis if the radiological criterion is associated 
with at least 1 clinical criterion 
Probable ankylosing spondylitis if  
1. Three clinical criteria are present 
2. The radiological criterion is present without any signs or 
symptoms satisfying the clinical criteria (other causes of 
sacroiliitis should by considered) 
 
Figure 1.2.1: Radiographic changes of sacroililiits 
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1.2.2 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) represents a whole spectrum of 
disorders which affect the gastrointestinal tract and includes two major 
entities, namely Crohn’s disease (CD) and ulcerative colitis (UC). CD is a 
transmural inflammatory disease that may involve any part of the 
alimentary tract, mainly the ileocolonic area and the perianal region, 
whereas UC is a mucosal disease with almost exclusive colonic 
involvement. This gut inflammation leads to symptoms of abdominal 
pain and (bloody) diarrhoea, and may result in different complications for 
which resective bowel surgery may be needed. The incidence of IBD is 
still increasing and responds to a lifetime risk for either one of the two 
diseases of about 0.5-1%. Worldwide, the incidence of UC seems to be 
higher than the incidence of CD, but in Belgium and France, CD seems to 
be more common than UC [Ekbom 2004]. Different treatment options are 
available, but interestingly, sulfasalazine and some TNF-α blockers are, 
similarly to SpA, also effective in CD [Panaccione 2004]. 
 
1.2.3. Shared pathogenic pathways in SpA and IBD. 
The pathogenesis of SpA and IBD is still unknown, but there is growing 
evidence that a disturbed handling of bacterial antigens might be an 
important pathway in both diseases. In CD, it has been hypothesized that 
different bacteria such as Yersinia, Listeria and Escherichia coli, may 
have an important pathogenetic role [Hugot 2003]. Especially strains that 
are able to invade, survive, and replicate in host cells without inducing 
cell death, such as the adherent invasive Escherichia coli (AIEC) strains, 
might be important to induce persistent intestinal inflammation, 
breaching the intestinal barrier and, activating macrophages [Glasser 
2001]. It can be hypothesized that this chronic intestinal inflammation 
may be a trigger for the occurrence of joint manifestations. Similarly, also 
in patients who primarily present with joint symptoms in the context of 
AS, ReA or uSpA, subclinical intestinal inflammation can be 
demonstrated [Mielants 1988, Mielants 1993, De Vos 1989, De Keyser 
1998]. Also immunological similarities between IBD and SpA could be 
demonstrated. The αEβ7 integrin is up-regulated on gut mucosal T cells 
from patients with inflammatory bowel disease and on gut mucosal T cell 
lined from AS patients [Elewaut 1998, Van Damme 2001a]. An impaired 
Th1 cytokine profile seems to have an important role in the pathogenesis 
of both SpA and CD [Van Damme 2001b, Van Damme 2001c]. A similar 
increase in expression of the E-Cadherin/catenin complex has been 
demonstrated in active subclinical gut inflammation in SpA and CD 
patients [Demetter 2000a, Demetter 2000b]. The colon mucosa of 
patients with SpA and CD is enriched with macrophages expressing the 
scavenger receptor CD163, which can also be found in the synovial 
membrane of SpA patients [Baeten 2002, Demetter 2005]. On the other 
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hand, the similarities between CD and SpA do not explain the full 
spectrum of SpA or CD. For example HLA-B27 is a major genetic 
susceptibility factor for AS and ReA, but is less frequently seen in 
patients with IBD-related SpA [Mielants 1993].  
 
1.3. Psoriatic arthritis 
PsA shares features from RA and SpA. Moll and Wright initially 
described PsA as a (seronegative) inflammatory arthritis with psoriasis 
and suggested a classification system into 5 groups (Table 1.3a) [Moll 
1973]. Since that time, a plea of other definitions and classification 
systems has been described. Moll and Wright proposed to consider 
patients with a positive RF as RA patients with concomitant cutaneous 
psoriasis. However, they indicated already that a positive RF may be due 
to false positivity (which can be found in about 5% of a healthy control 
population). Therefore, a working definition based on the presence of 
some features seemed to be helpful in distinguishing PsA from RA: a 
clinical inflammatory or radiographic enthesopathy, distal interphalangeal 
joint involvement, sacroilliitis or spinal inflammation, uncommon 
arthropathies, dactylitis and monoarthritis or oligoarthritis [McGonagle 
1999]. Also the initial classification into 5 subtypes (Table) was not 
easily applicable in clinical practice since the pattern of the disease may 
evolve during follow-up. Especially the polyarticular disease will become 
more prevalent during follow-up by evolution from oligoarticular to 
polyarticular disease [Marsal 1999, Kane 2003]. In order to resolve those 
classification problems, an international study is underway to define the 
optimal classification criteria for PsA by the CASPAR study group 
[Taylor 2005]. 
The treatment of PsA is very similar to the treatment of RA and consists 
of the use of NSAIDs and DMARDs [Mease 2004]. Also biological 
agents such as the TNFα-blockers are highly effective [Mease 2005].   
 
Table 1.3: Moll and Wright classification of psoriatic arthritis (1979) 
Skin psoriasis with spondylitis or arthritis 
1. Arthritis of the distal interphalangeal joints of the hands and feet 
2. Arthritis mutilans with sacroiliitis 
3. Symmetric arthritis indistinguishable from RA, but with negative 
RF 
4. Asymmetric pauciarticular arthritis with small joint involvement 
5. Ankylosing spondylitis with of without peripheral arthritis 
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2. Data analysis 
The markers, obtained by technical investigations and clinical measures 
can be used in the clinical decision-making. This section will show that 
markers should not only be statistically significant, but also clinically 
significant. We will discuss some selected methods to evaluate the 
clinical importance of a marker or a clinical measure and how they can be 
combined in prediction models and composite indices. 
 
2.1 The single variable  
The validation of a single marker or clinical measure can go through 
different steps. The available methods to validate a single variable highly 
depend on the characteristics of the variable. A variable is called 
continuous, when the variable is a scale, such as height, age, 
temperature… In contrast, a variable is categorical when it is described 
by a limited number of categories. The simplest categorical variable is a 
dichotomous variable with only two categories, e.g. sex, yes/no, 
present/absent.  When more than two categories exist, the variable can be 
described as multinomial or ordinal. A variable is ordinal when there is a 
certain hierarchy (e.g. good/better/best), in the other case it is called 
multinomial (e.g. 4 seasons). 
 
2.1.1 How to measure association? 
The exploration of a marker generally starts with the discovery that a 
certain marker is associated with a given disease. If the marker is 
continuous, an association will be reported if the height of the marker’s 
level differs between the two investigated populations. If the marker is 
dichotomous, an association will be reported if the frequencies of a 
positive test differ between the two investigated populations. A 
frequently reported measure for an association between dichotomous 
variables is the odds ratio (OR) [Bland 2000, Glas 2003]. The formula to 
calculate the OR is explained in Table 2.1.1.a. An OR of 1 indicates that 
there is no association, an OR > 1 indicates a positive association and an 
OR <1 indicates a negative association. An OR of > 2 or 3 is important 
and means that the odds for disease is 2 or 3 times higher when the test is 
positive. When 2 different markers are both associated with a certain 
disease, one should always look whether there is also an association 
between those 2 different markers. If this is the case, one should be aware 
that the Simpson’s paradox may occur. This paradox is described in 
Table 2.1.1.b [Simpson 1951] and proves that a reported association can 
disappear or invert after controlling for confounding variables. This can 
be seen both with dichotomous and continuous data and can be 
discovered by constructing 2x2x2 tables as displayed in Table 2.1.1.b 
[Agresti 1996]. More complex problems can be explored with logistic 
regression and general linear models which will be discussed later. 
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Generally, means, differences in mean, ORs… are calculated in a sample 
of the whole population and thus are in fact estimates of the real values of 
the whole population. This means that there may be a difference between 
this estimate and the real value. This uncertainty can be expressed by the 
95% confidence intervals which indicate that the true value has a 
probability of 95% of lying in this range [Henderson 1993].  
An alternative way to express this uncertainty is by means of p-values. 
This p indicates the probability that the null-hypothesis is true. In our 
example, we want to test whether the OR differs from 1. We thus can 
formulate a null-hypothesis that the OR is 1 and an alternative hypothesis 
that the OR differs from 1. When the 95% confidence interval for the OR 
does include 1, one must retain the null hypothesis and p will be more 
than 0.05. In the other case, when the 95% confidence interval for the OR 
does not include 1, we have less than 5% chance that the true OR is 1. In 
that case, the p-value corresponds to <0.05. 
 
Table 2.1.1.a: Calculation of an odds ratio 
cb
da
d
c
b
aOR
*
*==  
Disease 
 Present Absent (healthy) 
Positive
a 
number of diseased 
patients with positive test 
b 
number of healthy controls 
with a positive test Test 
Negative
c 
number of diseased 
patients with negative test
d 
number of healthy controls 
with a negative test 
 
 20 
Table 2.1.1.b: The example of the Simpson’s paradox as described by 
Simpson 
 
Condition 1: Condition 2: Death Penalty  
Victim’s Race Defendant’s Race Yes No % Yes 
White White 53 414 11.3 
 Black 11 37 22.9 
Black White 0  16 0 
 Black 4 139 2.8 
Total White (483) 53 430 11.0 
 Black (191) 15 176 7.9 
Legend :  
Simpson investigated whether there is a difference between whites and 
blacks to get the death penalty. This table may suggest that the white 
defendants have a greater chance to get the death penalty than blacks 
(11% whites vs. 7.9% blacks).  
However, after controlling for the victim’s race, it is clear that blacks get 
more death penalties: for killing a white victim 22.9% blacks vs. 11.3% 
whites get a death penalty; for killing a black victim, 2.8% blacks vs. no 
whites get the death penalty 
This paradox can be explained by the association between death penalty 
and defendant’s race, and by the association between victim’s race and 
defendant’s race. Blacks generally kill blacks and whites generally kill 
whites. Knowing that you have a greater change for a death penalty when 
you kill a white explains the initial higher number of death penalties for 
whites.  
 
 21 
2.1.2 Clinical value of a marker or measure 
An association should not only be statistically significant, but also 
clinically significant. This clinical significance highly depends on the 
application in which this marker will be used. In clinical practice, 
diagnosis and prediction are important aims. Diagnosis and prediction 
imply classification into categories. Methods to explore classification 
results will be discussed in the present chapter. 
 
2.1.2.1 Dichotomous data 
We reported already that the OR is an important measure to report 
association and that an OR of 2-3 may be clinically important. A lot of 
clinicians however don’t like this OR since it is not easy to understand 
what really happens. Therefore many other measures have been invented 
and are highlighted in Tables 2.1.2.1.a and 2.1.2.1.c. 
Table 2.1.2.1.a demonstrates that, applying a diagnostic test to a 
population of consecutive subjects with and without a certain disease will 
result in 4 possibilities. The number of true positives (TP) is the number 
of subjects that have the disease and a positive test, the number of true 
negatives (TN) is the number of subjects that do not have the disease and 
have a negative test. The two conditions that we want to avoid are: false 
negatives (FN= number of diseased subjects, but with a negative test) and 
the false positives (FP = number of non-diseased subjects with a positive 
test). Using those four possibilities, different ratios can be calculated to 
report the diagnostic properties of a test.  
A very intuitive ratio is the predictive value: the positive predictive value 
(PPV) of a test is the probability for a disease, given the test is positive 
and is the number of TP divided by the total number of subjects tested 
positive. The negative predictive value (NPV) is the probability of 
absence of disease given that a test result is negative and can be 
calculated by dividing the number of TN by the total number of subjects 
tested negative. The problem of reporting the PPV and NPV is that these 
ratios are only valid in a consecutive cohort of patients and depend on the 
prevalence of disease in that specific cohort, or in Baysian terms, PPV 
and NPV depend on the a priori chance of disease. Therefore, sensitivity 
and specificity are more frequently used to describe the diagnostic 
properties of a test.  
The sensitivity (sens) is the proportion of subjects with a positive test 
among the number of diseased subjects, and can be calculated by dividing 
the number of TP by the total number of diseased subjects. The 
specificity (spec) is the proportion of healthy subjects with a negative test 
result and can be calculated by dividing the number of TN by the total 
number of healthy subjects. Uncertainty of the estimates of sensitivity 
and specificity can be easily explored by the calculation of 95% 
confidence intervals [Harper 1999].  
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Another important ratio, especially for pure classification purposes is the 
accuracy. This is the number of TP and the number of TN divided by the 
total number of subjects. Again, this ratio depends also on the a priori 
chance of disease. The effect of the a priori chance on predictive value 
and accuracy can be calculated, applying Bayes’ theorem. This theorem 
says that the a priori chance can be changed into a posterior chance, 
adapted by new data and results. The mathematical formula and the 
application of this formula to calculate PPV in terms of sensitivity, 
specificity, and a priori chance (or prevalence of the disease), are 
explained in Table 2.1.2.1.b. Although sensitivity and specificity are 
independent of the a priori chance or the prevalence of disease, they may 
vary between study populations. The sensitivity of a marker may be less 
in patients with early disease. Also, false positive tests may be more 
frequent in certain subpopulations (such as elderly, patients with another 
disease) leading to a decrease of the specificity of the test. 
 
Table 2.1.2.1a: ratios to express association or diagnostic properties.  
  Disease 
  Present  Absent (healthy) 
Positive TP = True Positives FP = False Positives Test 
Negative FN = False Negatives TN = True Negatives
Odds ratio 
TN
FP
FN
TPOR =  
Relative Risk 
FNTN
FN
FPTP
TPRR ++=  
Positive predictive value )( FPTPTPPPV +=  
Negative predictive value )( FNTNTNNPV +=  
Specificity )( FPTNTNSpec +=  
Sensitivity )( FNTPTPSens +=  
Accuracy )()( FNTNFPTPTNTPAcc ++++=  
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Table 2.1.2.1.b: Bayes’ theorem and deduction of formula for PPV 
The Mathematical formula of Bayes’ theorem: 
P(D)
P(H)H)P(DD)P(H ⋅=  
(P = probability, H = hypothesis, D = data) 
Or in words:  
The probability of the hypothesis given the data [P(H|D)], is equal to 
the probability of the data, given that the hypothesis is correct 
[P(D|H)], multiplied by the probability of the hypothesis before 
obtaining the data [P(H)] divided by the averaged probability of the 
data [P(D)][Malakoff, 1999].  
Applied to diagnostic testing we can substitute the constituents of the 
formula: 
P(H|D) is the probability of disease if the test is positive (= PPV). 
P(D|H) is the probability of a positive test if disease is present 
(=sensitivity); 
P(H) is the a priori chance or prevalence for disease. 
P(D) is the probability of a positive test result in the total population 
under study (both diseased and non-diseased) [= number FP/ tot 
number of subjects = (1-spec)*(1-prev)]. 
The formula thus becomes: 
PPV=             a priori chance * sensitivity                              ...      
          Prevalence of a positive test in the total test population 
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2.1.2.2 Dichotomizing continuous data: ROC curve analysis 
A lot of markers have continuous properties, for which a certain cut-off 
can be chosen above which a test is considered positive. This is called 
dichotomizing the data and makes it possible to calculate sensitivities, 
specificities, but also PPV, NPV, accuracy… Generally, the definition of 
a high cut-off will reflect a high specificity with an impaired sensitivity. 
The definition of a lower cut-off will reflect a high sensitivity with an 
impaired specificity. How much the sensitivity decreases with increasing 
the specificity can be examined by the analysis of a receiver operating 
characteristics (ROC) curve.  This plots the sensitivity (as a measure of 
the true positivity rate) in function of the 1-specificity (as a measure of 
the false positivity rate) (Figures 2.1.2.2 a-b). The optimal diagnostic test 
will show no or only a small decrease in sensitivity, when a cut-off with 
higher specificity is chosen, and vice versa. A way to express this in an 
objective measure is the calculation of the area under the curve (AUC). A 
maximal AUC of 1 indicates the most optimal test. An AUC of 0.5 
indicates that the test has no diagnostic value. An accompanying table 
lists cut-offs, sensitivities and specificities (Figure 2.1.2.2.b) [Zweig 
1993, Greiner 2000]. AUC of ROC analysis can be used to compare 
different diagnostic tests: the best test is the test with the highest AUC. 
Differences between AUC can be evaluated statistically by means of the 
Hanley test [Hanley 1983]. 
The calculation of the AUC is one way to compare different tests: it may 
occur that the AUC of 2 tests may be identical, but that the curves are 
crossing [Hoffman 2005, Pepe 2003] (Figure 3.2.2.2). Therefore, 
additional comparison of sensitivities at equal specificity levels (or vice 
versa) may be useful. 
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Figure 2.1.2.2.a: Example of a continuous test  
 
 
Legend:  
We consider a continuous test 
that displays higher test result in 
diseased than in controls. This 
example will be used to explain 
ROC curve analysis, PPV, 
probabilities and logistic 
regression. 
 
Test 
result 
Number 
of 
Controls 
Number of 
Diseased 
patients 
Total 
1 5 0 5 
2 10 0 10 
3 45 0 45 
4 78 0 78 
5 92 1 93 
6 93 2 95 
7 92 4 96 
8 78 5 83 
9 45 7 52 
10 15 9 24 
11 5 11 16 
12 0 12 12 
13 0 13 13 
14 0 14 14 
15 0 13 13 
16 0 12 12 
17 0 11 11 
18 0 9 9 
19 0 7 7 
20 0 5 5 
21 0 3 3 
22 0 1 1 
Total 558 139 697 
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Figure 2.1.2.2.b: Example of a ROC curve 
Coordinates of the curve 
AUC = 0.966 
 
Legend:  
Based on the example of fig 2.1.2.2.a, 
we calculated sensitivities and 1-
specificities at each possible cut-off 
(Table). Plotting the sensitivities (y-
axis) in function of the 1-specificities 
(x-axis) results in the ROC curve 
(Figure) with an area under the curve 
(AUC) of 0.966. 
 
 
Test 
result 
≥ 
Sensitivity 1 – Specificity 
0 1.000 1.000 
1 1.000 .991 
2 1.000 .973 
3 1.000 .892 
4 1.000 .753 
5 .993 .588 
6 .978 .421 
7 .950 .256 
8 .914 .116 
9 .863 .036 
10 .799 .009 
11 .719 .000 
12 .633 .000 
13 .540 .000 
14 .439 .000 
15 .345 .000 
16 .259 .000 
17 .180 .000 
18 .115 .000 
19 .065 .000 
20 .029 .000 
21 .007 .000 
22 .000 .000 
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2.1.2.3 Using probabilities to handle a continuous test as such 
An important drawback of defining a cut-off is that information may get 
lost. The use of PPV requires the definition of a cut-off (in our example, a 
cut-off of 10 [greater than or equal to 10] has a specificity of 99% and 
PPV = 96%), which makes that the information gets lost that a patient 
who displays a result of 10 still has less chance to have the disease (38%) 
than a patient that displays a result of 12 (100%) (Figure 2.1.2.2.a and 
Figure 2.1.2.3.). This explains why the use of PPV at a certain cut-off 
may overestimate the chance.  
 
Figure 2.1.2.3: Comparison between probabilities and PPV 
 
 
Legend: 
The dotted line shows the PPV of a 
positive test for each possible cut-off. 
The continuous line shows the 
probability for disease for each test 
result. When the cut-off is defined at 
more than or equal at 9, the test has a 
PPV of 86%. However, the probability 
for disease when a result of 9 is 
present is only 13%. 
The figure and table is based on the 
case of Table 2.1.2.2.a 
Test 
result 
Calculated 
probability PPV 
1 0 0.21 
2 0 0.21 
3 0 0.22 
4 0 0.25 
5 0.01 0.3 
6 0.02 0.37 
7 0.04 0.49 
8 0.06 0.67 
9 0.13 0.86 
10 0.38 0.96 
11 0.69 1 
12 1 1 
13 1 1 
14 1 1 
15 1 1 
16 1 1 
17 1 1 
18 1 1 
19 1 1 
20 1 1 
21 1 1 
22 1 1 
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2.1.2.4 Introduction to logistic regression 
In the presented example (Fig 2.1.2.2a) the test could have 22 results and 
there were 697 subjects included. This made it possible to easily calculate 
the exact probabilities for disease given a certain test result (Figure 
2.1.2.4. However, a continuous test may have infinite possible results. In 
that case, it is impossible to calculate exact probabilities at each possible 
result. Therefore, a regression technique is needed which extrapolates 
between the observations. A probability (π) range from 0 to 1, therefore, 
the fitted regression curve should be S-shaped with a minimum of 0 and a 
maximum of 1. Such a S-shaped curve can be obtained by transforming 
the function of a straight line (y= α + βx) into π(x) = exp(α + βx)/(1+ 
exp(α +βx)). This can be alternatively written as log[π(x)/(1-π(x))] =  α + 
βx. The log [π(x)/(1-π(x))] is called “logit” which gave its name to this 
type of regression: logistic regression. The parameter β is the most 
important parameter and determines the rate of increase or decrease of the 
S-shaped curve. If β is zero, the curve becomes a horizontal straight line. 
Thus, if β=0, then the presence of disease is independent from the 
outcome of the test. If β≠0, the test can be used to predict disease or 
health. The parameters α and β and their confidence intervals are 
estimated through an iterative method. Figure 2.1.2.4 displays the 
predicted probabilities (as calculated by logistic regression) of the test of 
Table 2.1.2.2.a. compared to the exact probabilities for disease.  
In its more complex form, different tests or variables (x1,x2,…xi) can be 
combined resulting in the following formula : logit[π(x)] =  α + β1x1 
+β2x2+…+ βixi. If a variable x displays a parameter β that is not 
significantly different from 0, this means that this variable has no 
additional value in a model to predict the probability for disease. The 
variables (x1,x2,…xi) may be either continuous or dichotomous. In the 
case that the variable is dichotomous, the parameter β has another nice 
interpretation. The exponent of β [exp(β) = eβ] corresponds with the OR. 
If a model is fitted with only 1 variable, than exp(β) equals the OR 
calculated as described previously. In contrast, when a model is fitted 
with different explanatory variables, exp(β) can be interpreted as an 
“adjusted” OR. This may have important implications: as described by 
the Simpson’s paradox, an association can disappear, or even invert if 
adjusted for other variables when those variables are associated.  
Another difficulty that may arise is interaction. Interaction is the 
“statistical” term for what is better known as synergism in medical terms. 
For example, it can be assumed that a smoker has a 5% risk for a 
cardiovascular disease and a patient with diabetes has 2% risk for a 
cardiovascular disease. If a patient has both diabetes and smokes, those 
risks should be added. However when interaction occurs, the total risk for 
disease will be higher (or lower) than the sum of both risks. 
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Figure 2.1.2.4:  comparison between the exact and the predicted 
probabilities 
 
 
Legend : Comparison of the exact probabilities with the calculated 
probabilities of example 2.1.2.2.a. The S-shaped curve is calculated by a 
logistic regression function of the form  
logit[π(x)] =  α + βx with β= 1.1. 
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2.2 Combination of variables 
2.2.1 The role of combining variables in composite indices and prediction 
models.  
Generally, one single marker or one single clinical measure is not 
sufficient to classify, to make a diagnosis, or for predicting prognosis. We 
showed already that logistic regression can provide a helpful tool to 
calculate probabilities for a certain diagnosis or to predict a prognosis. 
Also disease activity can be described by combining different measures. 
This is especially important for rheumatic diseases, where it is 
impossible, due to their multifaceted aspects, to define disease activity or 
outcome by one single variable. In order to find the optimal prediction 
model, 2 cyclic steps should be taken: 1) feature selection, and 2) 
construction of the model. Different formal methods have been described, 
but it should be mentioned that a lot of composite indices have been 
constructed based on “gut feeling” and domain knowledge. We will 
describe only the formal methods hereafter. 
 
2.2.2 Feature selection methods 
2.2.2.1 Univariate 
A simple method to select variables is by selecting them based on the 
“height of association” with the outcome. This can be measured by p-
values, ORs, AUC of ROC curve analyses… The variables can thus be 
ranked based on those measures, and the highest ranked variables can be 
included in the model [Pepe 2003].  
 
2.2.2.2 Multivariate 
Feature selection methods that select a set of variables that have the best 
properties in the model is sometimes called multivariate. It may be 
possible that a single variable has good discriminative properties when it 
is tested by a univariate method, but that it performs badly in combination 
with others. Selecting a set of variables in a multivariate model can be 
done by the so-called forward or backward stepwise elimination. A 
forward stepwise method starts with one variable and scans all 
explanatory variables that can best be added. A backward method starts 
with all explanatory variables and scans which variables can best be 
eliminated without affecting the properties of the model.  
 
2.2.3 Classification methods 
2.2.3.1 Methods that require categorization of continuous variables 
A commonly used method to explore combinations of two (or more) 
variables is by defining a cut-off and exploring the diagnostic properties 
of “AND” and “OR” combinations, for which an “AND” combination 
means double positivity for the two markers and an “OR” combination 
means positivity for one of the two markers. Another technique which 
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requires categorisation of the data is the construction of decision trees. 
The use of decision trees allows a very comprehensive way of 
classification since it visualises different steps that should be taken to 
obtain the conclusion. They are quite easy to construct manually for 
simple datasets but require more sophisticated software for more complex 
datasets. Multiple classes can easily be modelled, but both decision trees 
and AND/OR combinations have the major drawback that continuous 
data should be categorised which may result in a loss of information.  
 
2.2.3.2 Methods that can handle continuous covariates as such: logistic 
regression and discriminant analysis. 
In contrast to decision trees, for which the output is categorical, the 
output of logistic regression and discriminant analysis is continuous 
which allows choosing an optimal cut-off in function of the purpose.  
Logistic regression has been explained previously. Classification into 
categories can be obtained when a cut-off is defined for the obtained 
predicted probabilities. 
The results of discriminant analyses are mostly quite similar to the results 
obtained by logistic regression, but the theory behind the method is 
somewhat different. Discriminant analysis attempts to find linear 
combinations of independent variables that separate the groups of cases 
optimally. These combinations are called discriminant functions and have 
the form displayed in the equation:  d = b0+b1x1+…+bixi where d is the 
value of the discriminant function, i is the number of (predictor) 
variables, b is the value of the coefficient and xi is the value of the case of 
the ith (predictor) variable. In other words, the method will try to find one 
(or more) functions that are linear combinations of the different variables 
(x1 to xi) by searching the coefficients (b).  
The procedure run with SPSS (Chicago, Illinois) automatically chooses a 
first function that will separate the groups as much as possible. It then 
chooses a second function that is both uncorrelated with the first function 
and provides as much further separation as possible. The procedure 
continues adding functions in this way until reaching the maximum 
number of functions as determined by the number of predictors and the 
numbers of categories in classification variable. The scores of the 
different discriminant functions can be used to designate the different 
categories. For simple classification problems, only 1 discriminant 
function is needed. 
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 Figure 2.2.3.2: Example of a discriminant analysis 
 
In this Figure, 2 markers were tested in 294 patients. We plotted the results of 
marker1 against the results of marker2 and represented each patient by 1 dot. 
The black dots are the diseased patients, the grey dot are the healthy controls. 
We performed discriminant analyses and the computer gave us the following 
discriminant function:  
D= -2.995 + 0.039 * Marker2 + 0.491 *Marker1 
Which can also be written as :  
Marker2 ⎟⎠
⎞⎜⎝
⎛−⎟⎠
⎞⎜⎝
⎛ +=
039.0
491.0
039.0
995.2 D
*Marker1 
This formula has the form of y=a-bx and thus represents a straight line with a 
negative (or descending) slope. A cut-off for D can be defined according to the 
classification results that are desired. For example: the dotted line represents a 
cut-off for D of 1.2 and will be able to discriminate especially diseased patients 
in the right upper corner. The black line is calculated with a cut-off for D of -
0.9 and will separate healthy controls in the left corner. The grey line is an 
intermediate line with a cut-off for D of 0.8. 
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2.2.3.3 Computer intensive methods including neural networks 
More sophisticated classification methods are available including: 
support vector machines (SVM), Kohonen self-organising maps, and 
multilayered perceptrons (MLP) (which are also called neural networks). 
They are promoted for more complex classification problems, such as 
non-linear classification problems and datasets with missing values. They 
are very flexible, and therefore, a defined classification model, obtained 
in the so-called training set, should always be confirmed in a test-set. 
This implies that those methods should be applied only to datasets that 
are big enough to be split in a train and test file [Cortes 1995, Kohonen 
1997, Haykin 1994, Ergun 2004].  
 
2.3 How to handle the dimension time? 
In statistics, time is a very important and powerful variable. However, to 
analyse time, specific statistical models are needed. In this paragraph, we 
will discuss methods to handle repeated measurements over time and 
survival analysis. 
 
2.3.1 Repeated measurements over time 
A common design of longitudinal studies is to measure a single outcome 
variable, for example swollen joint count, repeated at different time 
points. 
 
2.3.1.1 Classical methods 
Classically, differences between two different time points are measured 
by a paired sample test such as the paired t-test or the Wilcoxon Rank 
test. Those tests evaluate e.g. whether there is a difference between the 
baseline-state and the state after treatment. In order to control for a 
potential placebo effect, a control group must be included and should 
show no decrease or a significantly smaller decrease over time than the 
treatment group. Such methods, however can handle only 2 different time 
points. Therefore, it might be useful to calculate summary measures, such 
as an area under the curve (AUC) (Figure 2.3.1.1). AUC analysis can 
handle different measures in between the baseline measures and the last 
evaluation. 
When disease activity is compared between two treatment groups e.g. in a 
placebo-controlled trial, it is important to mention that not only the 
(mean) evolution of the disease activity over time should be evaluated, 
but also the number of patients that are finally in “remission” or present a 
pre-defined minimal disease activity [Wells 2005, Cook 2004, Schiff 
2002, Liu 1998]. 
 
 34 
Figure 2.3.1.1 Area under the curve analysis applied for longitudinal 
data. 
 
 
Suppose a treatment (R1) and a placebo arm (R2). Area under the curve 
analyses will compare the dark horizontal striped area with the light 
vertical striped area. 
 
 
2.3.1.2 General linear mixed models 
General linear mixed models (GLMM) are, similar to logistic regression, 
an extension of classical (linear) regression. For GLMM, the equation 
remains y=α+βx, but it allows a correction for repeated measurements 
within one individual. If you want to analyse the evolution of the weight 
over time in 5-year old children, one can take 100 children and measure 
them every 3 months in that year, thus obtaining 400 paired observations 
of height and weight from 100 children. To estimate the coefficients of 
the function “height= α + β*time”, those 400 observations should not be 
used as such, as every child has been measured 4 times. It can be 
assumed that there is a correlation between heights measured within each 
child. Therefore, a method should be used that can correct for the within-
child correlation of height. The GLMM’s provide different methods to 
handle such “within-child” correlations. Suppose 50 of those children are 
treated with a low caloric diet and 50 with a high caloric diet, and you are 
interested in the effect of the diet on the weight. In that case, the 
interaction or synergism between time and diet is of interest. This 
interaction term shows how the diet affects the weight over time. We thus 
will fit a model “weight=α+β1time + β2diet + β3 diet*time”. In both 
models, the final estimate of the effect of the diet will be given by the 
“diet*time” effect. The notation diet*time is used to express interaction. 
What are the advantages of such types of analyses? GLMM has the 
advantage that it is very flexible. In contrast to AUC analysis, GLMM 
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can not only handle measurements of more than 2 time points, but it can 
also handle unbalanced data (that time points may differ between 
patients). Not only one effect, but also different covariates can be 
included in the model, for example sex. Also missing values can be 
handled by GLMM upon the condition that the reasons for missingness 
can be retrieved or modelled by the data (for example, when missing 
values occur more frequently in patients with a high disease activity, and 
high disease activity is monitored in the dataset) [Fitzmaurice 2004, 
Renard 2002].  
 
2.3.2. Survival analysis 
A special case of modelling time is represented by survival analysis. This 
method evaluates at each time point the number of patients that are still 
alive (or that are still under treatment) compared to the number of 
patients that are already death (or stopped treatment). Differences 
between (treatment) groups can be compared by the so-called log-rank 
test (or alternative methods), but another extension of linear regression 
models, called Cox regression is more flexible. In analogy with logistic 
regression which gives an estimate of the OR, a Cox regression model 
provides estimates of the hazard ratio. The hazard ratio is a measure of 
the momentary risk to die (or to stop treatment).  
 
 36 
3. Selected biomarkers and clinical measures 
3.1. Genetic markers 
3.1.1 CARD15  
In 2001, 3 polymorphisms in the CARD15 (or NOD2) gene have been 
associated with CD by 2 independent researchers [Hugot 2001, Ogura 
2001]. Carriage of at least one polymorphism can be found in about 
38.5% - 57% of CD patients and in about 15% of controls [Hugot 2001, 
Ahmad 2002]. Different disease phenotypes have been associated with 
carriage of CARD15 polymorphisms, of which ileal disease seems to be 
the most strongly associated phenotype [Vermeire 2004]. The CARD15 
gene encodes for the NOD2 protein, which is constitutively expressed in 
myeloid cells as well as in Paneth cells. NOD2 expression can be induced 
under inflammatory conditions. The NOD2 protein is believed to serve as 
a microbial sensor by recognition of muramyl dipeptide (MDP), which is 
a peptidoglycan motif present in the cell wall of bacteria. The effect of 
the CARD15 polymorphisms on the activity of the receptor and the 
occurrence of disease remains to be further investigated [Eckmann 2005].  
 
Figure 3.1.1: The CARD15 gene 
 
3 polymorphisms of the CARD15 gene have been described  
SNP8 : R675W or 2023C>T 
SNP12 : G1881R or 2641 G>C 
SNP 13 : 980fs981X (frame shift) of 2936insC 
 
3.1.2 The HLA shared epitope 
The best-known genetic marker associated with RA is the HLA shared 
epitope (HLA-SE). This HLA-SE consists of one of the following motifs 
of amino acids QRRAA, QKRAA or RRRAA at positions 70-74 at the 
antigen binding groove of the DRbeta chain, shared respectively by HLA-
DRB1*01 (DBR1*0101, DRB1*0102), DRB1*04 (DRB1*0401, 
DRB1*0404, DRB1*0405, DRB1*0408), DRB1*1001 and others. 
Several studies found that one or two copies of the HLA-SE can be found 
more frequently in patients with RA (+/- 65%) compared to controls (+/- 
45%), and resulted in different hypotheses of its pathogenetic importance 
[Winchester 2004, Winchester 1999, Fries 2002]. Evidence has been 
given that carriage of one or two copies of the HLA-SE predisposes to 
more erosive disease, however large differences between ethnic groups 
exist [Moxley 2002, Gorman 2004]. 
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3.2 Serological markers 
3.2.1 ASCA 
Anti-Saccharomyces cerevisiae antibodies (ASCA) are directed against 
the cell wall mannan of Saccharomyces cerevisiae, commonly known as 
baker or brewer’s yeast [Sendid 1996]. The sensitivity and specificity of 
ASCA for CD range from 39% to 65% and from 80% to 97.5% 
[McKenzie 1990, Quinton 1998, Vermeire 2001, Sandborn 2001]. 
Combinations of ASCA with other serological markers such as pANCA 
or antibodies against bacterial antigens are under investigation to obtain a 
better serological tool for IBD [Mow 2004]. In CD patients, ASCA have 
been linked with earlier onset of disease, ileal involvement, penetrating 
and stricturing disease and need for resective bowel surgery [Quinton 
1998, Mow 2004, Vermeire 2001(2), Peeters 2001, Vasiliauskas 2000]. 
The pathophysiological role of ASCA is not yet clear [Main 1988, 
Oshitani 2004]. A genetic influence on ASCA formation has been 
suggested by family and twin studies: unaffected twins and unaffected 
relatives have higher ASCA titres compared to healthy controls [Seibold 
2001, Glas 2002, Lindberg 1992, Sutton 2000]. Interestingly, ASCA, 
only in its IgA isotype, can also be found in patients with SpA [Hoffman 
2003, Riente 2004, Torok 2004]. 
 
3.2.2. RA-associated antibodies: Anti-citrullinated protein/peptide 
antibodies (ACPA) and  rheumatoid factor (RF) 
The occurrence of RF in RA patients is well known since many years and 
constitutes one of the ACR criteria for RA [Arnett 1988]. RF is an 
immunoglobulin directed to the Fc part of IgG. Although different 
isotypes may be present, it is typically the IgM RF that is detected by the 
widely used agglutination assays such as the Waaler Rose test or the latex 
fixation test and by nephelometry. More recently, a group of antibodies 
that recognise citrullinated proteins or peptides have been described (anti-
citrullinated protein/peptide antibodies: ACPA). Substrates for such tests 
include citrullinated proteins (filaggrin, fibrinogen) or synthetic peptides. 
The history of ACPA has been reviewed by Peene et al [Peene 2004]. 
Shortly after the description of the anti-perinuclear factor (APF, detected 
by indirect immunofluorescence and directed against components in the 
perinuclear granules of human buccal mucosa cells) [Nienhuis 1964], 
also anti-keratin-antibodies (AKA, directed against epithelium of rat 
oesophagus) were reported to be associated with RA [Young 1979]. 
Moreover, it was shown that the epitopes recognised by both APF and 
AKA contain citrullinated residues, converted from arginine into 
citrulline by the enzyme peptidylarginine deiminase (PAD) [Sebbag 
1995, Girbal-Neuhauser 1999] (Figure 3.2.2.a).  
This knowledge of the epitope-specificity made it possible to develop 
more standardized and user-friendly tests. Substrates for such tests 
 38 
include deiminated proteins (filaggrin or fibrinogen) or peptides. The 
most widely available synthetic citrullinated peptide is known as CCP 
(cyclic citrullinated peptide). This substrate is available in an enzyme 
linked immuno sorbant assay (ELISA)-format [Schellekens 2000]. The 
first available CCP assay (anti-CCP1) was further optimized by screening 
of dedicated peptide libraries (anti-CCP2) [Vossenaar 2002]. Alternative 
peptides include pepA and pepB, which are detected by line immune 
assay (LIA) [Union 2002]. A recently described alternative citrullinated 
substrate is deiminated human antifibrinogen (AhFibA) [Nogueira 2002]. 
The reported sensitivity and specificity of the different tests may differ 
between studies. As mentioned in the statistics section, comparison 
between 2 diagnostic tests should be done on the same population using 
ROC curve analysis. Side-by-side comparison of ACPA and RF has been 
performed in different populations, indicating that ACPA has better 
diagnostic properties than RF testing [De Rycke 2004, Hoffman 2005, 
Nielen 2005]  
Fig 3.2.2 Citrullination  
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3.3. Single clinical measures and composite indices to evaluate 
disease activity in chronic arthritis. 
Multiple measures exist to evaluate disease activity and response to 
treatment. Amongst many others, they may include a measure for the 
number of swollen joints (swollen joint count), a measure for the number 
of tender joints (tender joint count, Ritchie articular index), a measure to 
evaluate systemic inflammation (ESR, CRP), functional measurements 
(morning stiffness, grip strength) and patient’s and physician’s 
questionnaires [Anderson 1989, Felson 1993]. An important tool in 
questionnaires is the visual analogue scale (VAS). The examinee has to 
evaluate for example his pain by placing a vertical line on a 100 mm line. 
Scores that are measured by VAS are the physician’s assessment of 
global disease activity, the patient’s assessment of global disease activity 
or the patient’s assessment of pain. 
A commonly used questionnaire is the health assessment questionnaire 
(HAQ) [Fries 1980], which measures disability. Another important 
questionnaire is the SF-36 [Ware 1992] and measures eight multi-item 
dimensions: physical functioning, social functioning, role of limitations 
due to physical problems, role of limitations due to emotional problems, 
mental health energy/vitality, pain and general health perception. 
In the early 90’s, it was common practice to use different of those single 
outcome measures to evaluate disease activity or response to therapy in 
placebo controlled trials. However, this imposed the problem of multiple 
comparisons [Bland 1995, Feise 2002, Curran-Everett 2002, Rothman 
1990]. This problem of multiple comparisons might be overcome by 
some specific statistical methods, which are in favour of the power, but at 
the expense of standardisation [Anderson 2003]. Therefore, composite 
indices were constructed, so that a single outcome measure could be used 
as the primary outcome, and thus corrections for multiple comparisons 
were no longer needed. Moreover, in the ideal situation, the new 
composite index should be more efficient than its single components to 
discriminate responders from non-responders. This leads to the 
construction of several composite indices, of which the best knowns are: 
the ACR response criteria [Felson 1995] (Table 3.3.a) and the disease 
activity score (DAS) [van der Heijde 1993]. The initial DAS has been 
later on transformed into the DAS28 [Prevoo 1995]. Also alternative 
disease activity scores have been proposed such as simplified disease 
activity index (SDAI) and clinical disease activity index (CDAI) [Smolen 
2003, Aletaha 2004] (Table 3.3b). For clinical trials, EULAR response 
criteria based on the DAS score have been developed also for the use in 
clinical trials [Van Riel 1996] 
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Table 3.3a:  ACR Response criteria (Felson, 1995) 
20, 50 or 70% improvement in 5 of 7 set variables 
Improvement in the first two is required 
Tender joint count 
Swollen joint count 
Acute phase reactant 
Patient’s pain 
Patient’s global assessment of disease activity 
Observer’s global assessment of disease activity 
Physical disability (HAQ) 
 
Table 3.3b: Formulas to calculate DAS and DAS28 based on three or 
four measurements 
SJC44/28 = 44/28 swollen joint count; TJC28 = 28 tender joint count; 
RAI =Ritchie articular index (53 joints in 26 units, graded for 
tenderness); ESR = Erythrocyte sedimentation rate 
Sqrt= squared root; Ln= natural logarithm; Conversion formula to 
calculate the DAS28 from the original DAS: DAS28 = (1.072)*DAS) + 
0.938 
Score  Formula 
DAS 
DAS based on RAI 
and 44 swollen joint 
count 
0.54*sqrt(RAI) + 0.065*sqrt(SJC44) + 
0.330*ln(ESR) + 0.0072*pt global VAS 
DAS-3 
DAS without pt global 
VAS 
0.54*sqrt(RAI) + 0.065*sqrt(SJC44) + 
0.330*ln(ESR) + 0.22 
DAS28 
DAS based on 28 
swollen and tender 
joint counts 
0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 
0.70*ln(ESR) + 0.014*pt global VAS 
DAS28-3 
DAS28 without pt 
global VAS 
[0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 
0.70*ln(ESR)]*1.08 + 0.16 
DAS28-
CRP 
DAS28 calculated 
with CRP in stead of 
ESR 
0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 
0.36*ln(CRP+1) + 0.014* pt global VAS 
+ 0.96 
DAS28-
CRP-3 
DAS28-CRP without 
pt global VAS 
[0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 
0.36*ln(CRP+1)] * 1.10 + 1.15 
SDAI 
Simplified disease 
activity score as a 
simple sum 
TJC28+SJC28+pt global VAS/10+phys 
global VAS/10+ CRP(mg/dl) 
CDAI 
Clinical disease 
activity score without 
CRP 
SJC28+TJS28+pt global VAS/10+phys 
global VAS/10 
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Table 3.3c: Definition of the DAS response criteria 
 Improvement in DAS 28 from Baseline 
 DAS28 at Endpoint >1.2 >0.6 and ≤ 1.2 ≤1.6 
≤ 3.2 Good Moderate None 
>3.2 and  ≤3.7 Moderate Moderate None 
>5.1 Moderate None None 
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4. Research objectives 
The aim of the present work was to explore the characteristics of different 
markers and measures in chronic arthritis.  
 
Before a marker can be used in clinical practice, this marker should be 
associated with the disease. Associations with the carriage of CARD15 
polymorphisms were investigated in the first part of this work. In 
Chapters 1 and 2, we investigated whether carriage of CARD15 
polymorphisms are associated with SpA-like features in Crohn’s disease 
patients and with Crohn-like features in SpA patients. In Chapter 3, we 
explored whether carriage of CARD15 polymorphisms is associated with 
the occurrence of ASCA. 
 
In the second part, we explored how a marker can be used in daily 
clinical practice by the exploration of the diagnostic characteristics of 
ACPA testing. In Chapter 4 we reviewed some association studies and 
the diagnostic properties of ACPA and RF. In Chapter 5, we investigated 
whether ACPA positivity, as a highly specific marker for RA, might 
occur in PsA. We investigated the diagnostic properties of different 
combinations of ACPA, SE and RF by means of calculations of 
probabilities in Chapter 6. In Chapter 7, we finally compared the 
diagnostic properties of tests and the agreement between different ACPA 
assays. 
 
Part 3 of this work aimed to evaluate different clinical measures and 
composite indices to measure response to treatment in RA and PsA. In 
Chapter 8, we investigated 511 RA patients under infliximab therapy that 
where enrolled in a compassionate use program. After a loading regimen 
at week 0, 2, 6 and14, the treating rheumatologist could decide to give a 
dose increase. This decision to give a dose increase can be considered as 
a measure of insufficient response. In the analysis presented, we 
investigated which single measures and composite indices could best 
discriminate this decision and whether they can be combined in a 
composite index. In Chapter 9, we evaluated the 4 years effect of 
infliximab therapy and how the DAS28 can be used to measure sustained 
response to therapy and which measure or composite index can be best 
used to predict the survival of the therapy. Finally, we evaluated in 
Chapter 10 whether the measurement of DAS28 can also be used in PsA 
patients.  
 
In the last part (Chapter 11), we evaluated different methods to construct 
prediction models by computer intensive methods. Discriminant analysis 
and logistic regression may be less performing in real life datasets with 
missing values and high dimensionality. Therefore, we evaluated whether 
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different computer intensive methods can handle those problems more 
effectively.  
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Abstract 
Objectives:  In the present analysis, our objective was to calculate the 
probabilities for rheumatoid arthritis (RA) in a consecutive cohort of 
patients during diagnostic work-up. Therefore, we fitted different logistic 
regression models evaluating the value of HLA-shared epitope (SE) 
determination and testing for rheumatoid factor (RF) and anti-
citrullinated protein/peptide antibodies (ACPA). 
Methods: The study included 1003 consecutive patients, presenting a new 
diagnostic problem for which RA was included in the differential 
diagnosis. All patients were tested for ACPA, RF and HLA-SE.  
Results: After 1 year, diagnoses were established: 153 patients had 
definite RA and 629 patients had RA excluded. RF, used as a continuous 
marker is useful to evaluate the probability for RA. Combined RF and SE 
testing may provide additional predictive information, but combined 
ACPA and RF testing is superior. The redundancy of SE testing in a 
model that includes ACPA testing can be explained by the high 
association between ACPA and SE both in RA and non-RA patients. The 
value of RF testing increased if patients presented with at least one 
swollen joint at baseline. 
Conclusion: In the present study, we calculated valid probabilities for RA 
during routine diagnostic work-up and showed that the potential 
additional value of SE testing disappears when ACPA testing is available. 
Combined RF and ACPA testing is useful, especially when RF is 
considered as a continuous parameter reflecting an increasing probability 
for RA at higher RF titers. The value of (continuous) RF testing increases 
when the a priori chance is higher.  
 
INTRODUCTION 
Diagnosis and intensive treatment at an early stage in case of rheumatoid 
arthritis (RA) is an important factor in slowing the radiological 
progression [1]. Although the diagnosis of RA is mainly based on clinical 
features, these might be insufficient in an early stage of the disease, 
hampering clinical diagnosis. Therefore, additional serological and 
genetic tests may be useful. The oldest and best-known serological 
antibody (Ab) test is the rheumatoid factor (RF), which is part of the 
revised American College of Rheumatology (ACR) criteria for RA [2]. 
More recently, anti-citrullinated protein/peptide antibodies (ACPA) have 
been described. These are highly specific markers for RA and combine a 
good sensitivity (45 to 80%) with a very high specificity (89 to100%) 
[3,4,5]. Detection of ACPA can be achieved using the antigenic 
substrates citrullinated peptide A (pepA) and citrullinated peptide B 
(pepB) incorporated in a line immunoassay (LIA®) [6], or by ELISA tests 
that are available for cyclic citrullinated peptides (CCP) [7] and 
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deiminated fibrinogen [8]. All those last generation assays display 
comparable sensitivities and specificities [4,9]. Genetic markers might 
also have a role in RA diagnosis; much attention has been given to the 
HLA shared epitope (SE), which is found more often in RA patients than 
controls [10,11]. Since RF was the only available serologic marker until 
relatively recently, although not recommended, an additional assessment 
for the presence of the SE was sometimes performed.  
Combinations of RF, SE, and ACPA have been used as such, or with 
other clinical or radiological measures, in models to predict RA or 
radiological progression [12,13,14]. The predictive value of these models 
depends on 1) the characteristics of the investigated population and 2) the 
prevalence (or a priori chance) of RA or persistent erosive disease, 
varying from 24.2% to 68% between different early arthritis cohorts 
[12,15].  
Although most of these models have been applied in early arthritis 
cohorts, few data are available about the combined value of RF, SE and 
ACPA testing for RA diagnosis in a routine clinical diagnostic set up. 
The aims of the study were threefold: to test the value of RF, ACPA and 
SE profiles in different models to evaluate the probability for RA; to 
assess the added value of SE and RF testing now that ACPA testing is 
widely available; and to investigate the optimal combination of these 
three parameters. 
 
PATIENTS AND METHODS 
Patients 
The present analysis is based on a prospective study in which 1003 
consecutive patients from three academic and nonacademic centers were 
enrolled [16]: the Department of Rheumatology, Ghent University 
Hospital (Ghent, Belgium); the Locomotor Center, Elisabeth Hospital 
(Sijsele-Damme, Belgium); and the Department of Rheumatology, St-
Augustinus Hospital (Wilrijk, Belgium). The local ethics committees 
approved this study October 1997, and informed consent was obtained 
from all patients. Patients were included from november 1997 to 
December 1999. 
Patients were seen by one of the participating rheumatologists and 
entered consecutively the study if they presented with a new diagnostic 
problem for which RA was included in the differential diagnosis. This 
setting typically reflects the case where a rheumatologist would request 
RF or ACPA testing. Blood was taken at inclusion; serum samples 
obtained were aliquoted and frozen at –20°C, and whole blood was stored 
at -80° C. Participating rheumatologists were asked to fill in a file at 
baseline and after one year of follow-up asking for the clinical diagnosis 
established by the treating rheumatologist by ticking a box containing one 
of the following diagnoses (in ascending probability for RA): definite 
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non-RA, potential RA, proable RA and non-RA. To improve the 
comparability of our results, further classification of all RA patients was 
performed after one year by systematically checking the (cumulative) RA 
classification criteria by an independent investigator [2]. Patients 
fulfilling both the clinical diagnosis for definite RA and the classification 
criteria were further taken into account as RA patients. Patients in which 
RA was excluded were taken as the non-RA control group. 
 
Rheumatoid factor  
RF was determined by the latex fixation test. A suspension of uniform 
polystyrene particles sensitized in glycine buffer with heat-altered human 
IgG (Difco Laboratories, Detroit, MI) was diluted 1/20 and incubated 
with progressive dilutions of human sera in microtiter wells. The reagents 
were mixed and incubated at 37°C for 2 hours. The plates were then 
shaken gently and inspected for observable agglutination. Titers were 
converted to U/mL using a reference serum, to correct for inter-assay 
variation.  A low (>95% specificity level, 25 U/ml) and a high (>98% 
specificity level, 100U/ml) cut-off was defined based on a previously 
described cohort [4] 
 
Detection of anti-pepA antibodies by line immunoassay (LIA®).  
Anti-pepA Ab were detected by a research LIA® containing the synthetic 
citrullinated peptide referred to as pepA (INNO-LIA™ RA - for research 
use only - Innogenetics, Ghent, Belgium) [4,6]. Air-dried strips were 
scanned using a HP Scanjet 5P scanner. A reference sample was included 
in each test run. In order to minimize test-to-test variability, the scan 
values of individual samples were corrected by dividing them by the scan 
values of the cut-off sample. Anti-pepA positivity was defined as a 
corrected scan value of ≥1, at which the test had a specificity of ≥ 98.5% 
and a sensitivity of 63.6% in an independent cohort of patients [4].  
 
HLA typing by INNO-LiPA (line probe assay) technology 
DNA was extracted from whole blood samples and amplified using the 
INNO-LiPA HLA-DRB1 or –DRB decoder amplification kits 
(Innogenetics, Ghent, Belgium) as instructed by the manufacturer. HLA 
typing was performed with the INNO-LiPA HLA-DRB1 or –DRB 
decoder kits (Innogenetics, Ghent, Belgium), that are based on the reverse 
hybridization principle; specific oligonucleotide probes are immobilized 
as parallel lines on membrane-based strips. The amino acid sequences 
QRRAA, QKRAA, and RRRAA at positions 70-74 constitute the RA SE 
sequence. Patients were classified into two groups according to the 
inheritance of zero versus one or two copies of the SE.  
 
Statistical methods 
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The dataset, previously described [16], is here analyzed by logistic 
regression techniques. Different models with all possible combinations of 
anti-pepA Ab, SE and RF-results as explanatory variables and RA 
diagnosis as explained variable were fitted with logistic regression. The 
validity of the models was confirmed by fitting a full model and 
performing backwards elimination of the interaction terms. Logistic 
regression models are an extension of the general linear regression and fit 
S-shaped curves by modeling the logit [= log(x/(1/x))] of the probabilities 
for a dichotomous outcome, in this case, the probability for RA (= π), 
using the formula logit(π) = log(π/(1-π)) =  α + β1x1 +β2x2+…. The 
predicted probabilities thus obtained can be plotted against the different 
explanatory variables x [17]. This method allows to evaluate the variables 
in a continuous way and to visualize the models so that they are easier to 
interpret.  
We calculated odds ratios and their 95% confidence intervals, as a 
measure of the correlation between dichotomous variables. Homogeneity 
between marginal odds ratios were calculated with the Breslow-Day 
statistic. Common odds ratios were calculated by means of the Mantel-
Haenszel test [17].  
The analyses were performed using 2 classical statistical packages: SPSS 
12.0, Chicago, Il, USA and S-Plus 6.1, Insightful Corporation, Seattle, 
USA. 
 
RESULTS 
Patient characteristics 
After one year of follow-up, the treating rheumatologist diagnosed each 
patient according to the following categories: definite RA (n = 153), 
probable RA (n = 72), potential RA (n = 75), non-RA (n = 629), or lost to 
follow-up (n=74). Only patients diagnosed by their treating 
rheumatologist as definite RA and fulfilling the revised ACR criteria for 
RA [2] were further considered in the RA-group (n = 144). The non-RA 
control population (n=629) had the following diagnoses: osteoarthritis 
(38%), abarticular rheumatic symptoms (including peri-arthritis 
scapulohumeralis, non-rheumatic tendinopathies,…) (14%), 
spondyloarthropathy (10%), connective tissue diseases including 
polymyalgia rheumatica (15%), psoriatic arthritis (7%), crystal induced 
arthritis (1%), fibromyalgia and aspecific arthralgias (5%), other and 
undifferentiated diseases including infections, malignancies and 
neurological disorders  (10%). We finally lost 9 non-RA patients and 3 
RA patients, due to lack of serum or DNA samples of good quality. The 
mean age of the RA patients was 58 year and 51 year for the non-RA 
patients. In both populations, 66% of patients were female. The mean 
duration of symptoms was 19.3 months in the RA group and 15.9 months 
in the non-RA group. We further identified a subpopulation of 498 
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patients with at least 1 swollen joint at baseline including 134 RA and 
230 non-RA patients.  
 
Test results 
Six hundred twenty non-RA and 141 RA patients were tested for anti-
pepA Ab, RF and SE. A positive anti-pepA result was observed in 78 
(55.3%) RA and 13 (2.1%) non-RA patients. Median pepA scan values 
were 2.15 (range 0-9.62) for RA patients and 0.04 (range 0.00-6.07) for 
non-RA patients. Ninety (63.8%) RA and 264 (42.6%) non-RA patients 
carried at least one copy of the SE. Two copies were found in 32/141 
(21.1%) of the RA patients and in 30/620 (5.1%) of the non-RA patients. 
The median RF titers were 50 U/ml (range 0-1600) for the RA and 0 
U/ml (range 0-1600) for the non-RA patients.  
 
Comparison between PPV and predicted probabilities.  
Plots of the positive predictive values and predicted probabilities in 
function of RF titers are shown in Figure 1.  Positive predictive values 
(PPV) were calculated by defining different cut-offs at different titer 
steps and plotted against RF or anti-pepA Ab titers (Figure 1a). Predicted 
probabilities, calculated by logistic regression, are shown in Figure 1b. 
 
Logistic regression models in the global population 
Different logistic regression models were fit with different combinations 
of anti-pepA, RF and SE-testing. These analyses revealed that ACPA 
testing in combination with SE has no additional value. This resulted in 2 
final models: 1) a model with combined RF and SE testing, and 2) a 
model with combined RF and ACPA testing. The results of these 2 
models are visualized in the predicted probability plots in Figure 2 and 
Figure 3, showing that the added value of combined RF and SE testing is 
limited compared to combined RF and ACPA testing. 
 
Logistic regression models in the subpopulation of patients with at 
least 1 swollen joint at baseline. 
Similarly as observed in the global population, (continuous) RF testing 
has additional value to ACPA testing alone. Moreover, in this sub-
population with at least 1 swollen joint, additional (continuous) RF 
testing seems to add more value than in the global population: lower RF 
titers become more relevant. The predicted probability curves are shifted 
up and have steeper slopes (Figure 4). 
 
Correlation between SE and anti-pepA Ab positivity 
When the dataset was split into RA and non-RA patient groups, we 
obtained the following marginal odds ratios for the association of anti-
pepA Ab positivity with SE-positivity: 4.63 (95% CI 1.26-17.00, p= 
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0.011) for non-RA patients and 4.21 (95% CI 2.03-8.74, p<0.001) for RA 
patients. Application of the Breslow-Day test indicated that the ORs for 
the association between SE and anti-pepA Ab positivity were not 
significantly different (which also means that there is no interaction 
between SE and anti-pepA Ab positivity). This allowed us to calculate an 
overall common odds ratio for the relation between anti-pepA Ab 
positivity and SE positivity, which was 4.31(95% CI 2.28-8.17, p<0.001).  
 
Correlation between the SE and RF positivity 
The odds ratios for RF positivity with SE positivity at the low cut-off 
were 0.72 (95% CI 0.42-1.24, p = NS) for the non-RA patients and 3.1 
(95% CI 1.5-6.5, p= 0.002) for the RA patients. Using the high RF cut-
off, the ORs were 0.5 (95% CI 0.165-1.716, p=NS) for the non-RA 
patients and 2.8 (95% CI 1.3-5.8, p=0.008) for the RA patients. However, 
when corrected for anti-pepA Ab positivity, the significant association 
between RF and SE, initially observed in the RA population, disappeared. 
The ORs thus obtained were 1.7 (95% CI 0.5-3.1, p = NS) at the low RF 
cut-off and 1.7 (95% CI 0.7-3.8, p= NS) using the high RF cut-off.  
 
DISCUSSION 
The set-up of the present study represents real-life clinical practice by the 
inclusion of consecutive patients seen by a rheumatologist (2 non-
academic centres, 1 university centre), for a new diagnostic problem in 
which RA was included in the differential diagnosis. After 1 year, 
diagnoses were established as RA, non-RA and a group of patients with 
persistent undifferentiated disease. In order to avoid misclassifications, 
the patients with persistent undifferentiated disease were further excluded 
from the present analysis. Such a study design allows the calculation of 
representative predictive values and the estimation of representative 
probabilities for RA. This contrasts with other types of case-control 
studies where the calculated predictive values should not be extrapolated 
since predictive values depend on the prevalence (or the a priori chance) 
of the disease [16,18,19]. In contrast to the classical exploration by means 
of sensitivity, specificity, and predictive value, we evaluated the 
(predicted) probabilities for disease (figures 1b, 2b, 3 to 6). The use of 
probabilities is especially helpful when a continuous marker that is 
known to express higher titers in diseased than in non-diseased patients is 
considered (which is the case for both RF testing). The use of positive 
predictive values (PPV) requires the definition of a cut-off point (for 
example, an RF cut-off at 25 U/ml, which corresponds with a PPV of 
61.5% in the present study). This cut-off has the disadvantage that the 
information gets lost that a patient who displays a titer of 100 U/ml still 
has a greater chance to have RA than a patient who displays only 25 
U/ml. Therefore, the use of PPV may overestimate the probability for 
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disease in patients displaying low positive titers (figures 1a and 2a 
compared with figure 1b and 2b). In the present analysis, we used logistic 
regression to calculate those probabilities. Although logistic regression is 
a parametric regression technique and therefore provides only an estimate 
for the probabilities  by extrapolation, it has the great advantage that it 
easily allows the exploration of combinations of different markers in a 
continuous and categorized manner. This is in contrast to the commonly 
used “and/or combinations” at pre-set sensitivity or specificity levels for 
which dichotomization by defining a cut-off is needed [15, 16, 20].  
Plotting (predicted) probabilities by means of logistic regression, as 
performed in the present analyses should not be confused with the 
cumulative probability plots, described by Landewé [21].  
We thus calculated (predicted) probabilities for RA by means of logistic 
regression, using different combinations of RF, the presence of SE and 
anti-pepA Ab testing. These analyses demonstrated that SE testing did 
not significantly contribute to a model where anti-pepA Ab testing is 
already present. In contrast, SE testing contributed significantly when 
only RF testing was performed (Figure 2). The redundancy of SE testing 
when ACPA testing is available was also demonstrated in a model for 
prediction of radiological progression and persisting erosive disease [12, 
14]. This redundancy of SE testing when ACPA testing is available can 
be explained by the high association (without interaction for diagnosis of 
RA) between SE and ACPA in RA and non-RA patients (OR = 4.3). It is 
important to highlight that this association between ACPA and SE is also 
observed in non-RA patients. The association between ACPA and SE has 
also been described in patients with RA and undifferentiated arthritis and 
has led to hypotheses about the induction of ACPA [3,22-30]. 
Interestingly, this association between ACPA and SE might also be the 
reason for the observed association between RF and SE, which disappears 
after correction for ACPA positivity. Berglin et al showed that combined 
testing for ACPA and SE had an additional value for predicting RA in 
healthy blood donors [27]. This can be explained by the fact that some 
SE-positive blood donors who later developed RA had not(yet) detectable 
ACPA at the time of blood sampling: only 16/34 (47%) of the SE-
positive patients who later developed RA were ACPA positive (in 
contrast to 78% in the present study).  
In contrast to the clear association between ACPA and the SE, there 
seems to be no (or only a weak) correlation between RF and the SE 
[4,22,23]. This explains why combined SE and RF testing displayed a 
statistically significant additional value to RF testing alone, as displayed 
in Figure 2. However, this additional value is limited when compared to 
to the important additional value provided by the combination of ACPA 
and RF testing (described in Figures 3).  
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Interestingly, these models show also that the probability for RA, given a 
positive ACPA test, is less than 80% when RF is negative, but increases 
when higher RF titers are present. At very high RF titers, the value of 
additional ACPA testing appears to be reduced (Figure 3). In contrast, 
ACPA has more added value when only intermediate positive RF titers 
are displayed. The models from Figures 1-3 have been calculated in a 
population of patients in whom the treating rheumatologist would 
routinely ask for a rheumatoid factor test. We also evaluated the value of 
RF and ACPA testing in the subgroup of patients with at least one 
swollen joint at baseline (Figure 4). These figures show that intermediate 
RF titers become more relevant when the a priori chance for RA is 
higher.  
These findings might be used to propose multi-step testing models in 
which different RF cut-offs are defined. In such models, additional 
ACPA testing might not be required in patients with a high positive RF 
test or in patients with an intermediate high positive RF but with a high 
clinical probability for RA [13]. In contrast, additional ACPA testing 
seems to add much value in cases with low positive RF.  The value of the 
combined testing of RF and ACPA has also been demonstrated in models 
of early or undifferentiated arthritis to predict RA or erosive disease 
[12,32,33]. Logistic regression can be useful to evaluate the diagnostic 
value of different lab tests by different models and plots. The conditions 
for the generalization of those models and plots are similar to the 
conditions to generalize predictive values (PPV, NPV): populations and a 
priori chance for disease should be similar [34]. Logistic regression can 
also be used to construct prediction models including variables from 
medical history and physical examination, but generalization of such 
models may be more difficult when more variables are used [12, 35, 36]. 
To conclude, this study provides unbiased models to calculate the 
probabilities for the development of RA in a diagnostic set-up. Although 
not recommended in daily clinical practice [37], we showed that, in case 
ACPA results are not available, SE-testing may add some diagnostic 
information in addition to RF results. However, since ACPA testing has 
become available, additional SE testing seems no longer appropriate in a 
diagnostic work-up, due to the high correlation between ACPA and the 
SE. Finally, it would appear that a diagnostic strategy that combines 
ACPA testing and RF-testing in a single or multi-step method, is superior 
to single RF or single ACPA testing alone. RF testing is especially useful 
when it is considered as a continuous parameter that reflects a higher 
probability for RA when higher titers are displayed. 
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FIGURES 
 
Figure 1: Plots of PPV and predicted probability of RF. 
(a) PPV were calculated by defining different cut-offs at different 
titers. (b)Predicted probabilities were calculated by logistic 
regression.  
 
Figure 2: Plot of the predicted probabilities in function of RF 
titers and SE testing. 
This figure illustrates that SE testing has a small additional value to 
RF testing for the diagnosis of RA. 
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Figure 3: Plots of the predicted probabilities in function of RF 
titers and ACPA testing 
 
 
This figure illustrates that ACPA testing has a big additional value 
to RF testing, especially in the low RF range.  
 
Figure 4: Plots of the predicted probabilities in function of RF 
titers in patients with at least one swollen joint at baseline. 
 
 
In this figure, we evaluated the effect of the baseline presence of at 
least one swollen joint on the interpretation of RF results. In figure 
4a, we evaluated single continuous RF testing in patients with at 
least one swollen compared with the model from Figure 3 (red). In 
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figure 4b, we evaluated a model of combined RF – ACPA testing 
calculated in the global population (red, Figure 3) compared with a 
model calculated in the subgroup of patients with at least 1 swollen 
joint at baseline (blue). 
 
 111 
ADDITIONAL TABLES 
Table : Different logistic regression models to predict RA  
 
Model 1: pepA-RF-SE 
 Beta OR 95%CI p-value 
Intercept -2.445     
PepA scan value 1.065 2.90* 2.14 3.92 <0.001 
RF titer 0.006 1.01* 1.00 1.02 0.002 
SE 0.219 1.25 0.76 2.08 NS 
Model 2: pepA-SE 
 Beta OR 95%CI p-value 
Intercept -2.291     
PepA scan value 1.287 3.62* 2.67 4.91 <0.001 
SE  0.113 1.12 0.69 1.81 NS 
Model 3: RF-SE 
 Beta OR 95%CI p-value 
Intercept -2.380     
SE 0.769 2.15 1.40 3.30 <0.001 
RF titer 0.016 1.03* 1.00 1.02 <0.001 
Model 4: pepA continuous-RF trichotomous 
 Beta OR 95%CI p-value 
Intercept -2.535     
PepA scan value 0.925 2.52* 1.81 4.08 <0.001 
RF low positive 1.404 4.073 1.74 9.52 0.001 
RF high positive 1.191 3.292 1.16 9.32 0.025 
Model 5: pepA positive-RF continuous 
 Beta OR 95%CI p-value 
Intercept -2.325     
Anti-pepA positivity 3.676 39.5 18.6 83.7 <0.001 
RFtiter 0.007 1.01* 1.00 1.02 <0.001 
Model 6: pepA positive-RF continuous 
in patients with at least one swollen joint at baseline 
 Beta OR 95%CI p-value 
Intercept -1.608     
Anti-pepA positivity 3.537 34.359 7.739 152.534 <0.001 
RFtiter .023 1.023 1.013 1.033 <0.001 
* The OR for the continuous parameter RF or anti-pepA Ab should be 
interpreted differently from the OR for the dichotomous anti-pepA Ab 
and SE testing [34].  
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Table:  Results of the test in the different subpopulations of the 
cohort. 
 
Diagnosis 
n 
(included 
in study) 
n 
(complete 
case) 
RF 
LF 
low 
RF 
LF 
high
pepA
HLA-
SE 
positive 
Lost to follow-up 74 73 11% 4% 7% 49% 
Definite RA,  
ACR criteria 
fulfilled 
144 141 69% 42% 55% 64% 
Definite RA,  
ACR criteria not 
fulfilled 
9 9 40% 20% 30% 67% 
Probable RA,  
ACR criteria 
fulfilled 
37 36 35% 24% 22% 65% 
Probable RA,  
ACR criteria not 
fulfilled 
35 34 29% 17% 18% 45% 
Potential RA 75 75 13% 5% 7% 44% 
Non RA 629 620 10% 2% 2% 43% 
Overall 1003 988 16% 10% 11% 47% 
RFLF low >/= 25 U/ml  
RFLF high >/= 100 U/ml 
pepA >/= 1 
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CHAPTER 7 
 
Diagnostic value of anti-human citrullinated fibrinogen ELISA and 
comparison with four other anti-citrullinated protein assays.  
 
Vander Cruyssen B*, Cantaert T*, Nogueira L, Clavel C, De Rycke L, 
Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De 
Keyser F.  
 
Arthritis Res Ther. 2006 Jul 19;8(4):R122   
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CHAPTER 8 
 
A. 
DAS28 best reflects the physician's clinical judgment of response to 
infliximab therapy in rheumatoid arthritis patients: validation of the 
DAS28 score in patients under infliximab treatment. 
 
Vander Cruyssen B*, Van Looy S*, Wyns B, Westhovens R, Durez P, 
Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, Malaise 
M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. 
 
Arthritis Res Ther. 2005;7:R1063-71. 
*Equal contribution 
 
B. 
DAS28: a useful instrument to monitor infliximab treatment in patients 
with 
rheumatoid arthritis. 
 
van Riel PL, Fransen J. 
 
Arthritis Res Ther. 2005;7(5):189-90. 
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CHAPTER 9 
 
Four year follow-up of infliximab therapy in rheumatoid arthritis patients 
with longstanding refractory disease: attrition and long-term evolution of 
disease activity. 
 
Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van 
den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen 
L, Vastesaeger H, Geldhof A,  Boullart L, De Keyser F. 
 
Arthritis Research & Therapy 2006, 8:R112 
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CHAPTER 10 
 
Comparison of different outcome measures for psoriatic arthritis patients 
treated with infliximab or placebo. 
 
Vander Cruyssen B, De Keyser F, Kruithof E, Mielants H, Van den 
Bosch F. 
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LETTER TO THE EDITOR 
Psoriatic arthritis (PsA) shares features with the spondyloarthropathy 
(SpA) concept and with rheumatoid arthritis (RA). Treatment of PsA 
should target the skin, the SpA-like features and the RA-like features of 
the disease. Effects of therapy can be measured by one index that covers 
different axes at once or by evaluating each axis separately [1]. In the 
present analysis, we aimed to evaluate different composite indices that 
have been validated in RA and compare with the Psoriatic Arthritis 
Response Criteria (PsARC) [2].  
The study population consisted of eighteen PsA patients, previously 
enrolled in a randomized mono-center double-blind placebo-controlled 
study evaluating infliximab in SpA [3]. This study included 18 PsA 
patients of whom 9 received placebo. Patients were evaluated at baseline 
and weeks 1, 2, 6, 8 and 12 which included the evaluation of the single 
components included the PsARC, DAS28 [4] and DAS response [4]. A 
modified ACR (mACR) response was calculated by using the BASFI or 
the Dougados functional index in stead of the HAQ [5, 6, 7].  
Although only 18 patients were included in the present study, this was 
enough to evaluate the value of the different outcome measures in 
psoriatic arthritis as reflected by the significant differences between 
groups after treatment. The results of the mACR response were identical 
when BASFI or Dougados functional index were used. PsARC response, 
mACR20 response and DAS28 response were similarly effective to 
discriminate the 2 treatment groups (Table 1). The mACR response and 
the DAS28 response can not only be used as a dichotomous (response yes 
or no) variable, but also as ordinal variables (0-20-50-70 response for the 
mACR response and no-moderate-good response for the DAS28). The 
evaluation of such ordinal categories by a special measure of association 
(such as the ordinal gamma statistic [8]), adds statistical power (Table1).  
DAS28 as a continuous variable can be evaluated by measuring changes 
over time or by comparing the remaining disease activity at week 12 
between the two treatment arms (Table 1). The effect size (ES) [10] and 
standardized response mean (SRM) [9] of DAS28 were respectively 1.9 
and 1.7 in the infliximab treated group which is similar for PsA as for RA 
(personal observations). Profiles over time can be evaluated by the 
comparison of areas under the curve (Table1) or by linear mixed models 
analysis. Mixed models analysis can correct for small differences in 
baseline conditions between groups [10]. We therefore fitted a general 
linear mixed model with DAS28 as outcome variable resulting in a 
significant effect of the treatment over time, reflected by a significant 
treatment effect at week 2 (mean = -1.15 vs. baseline, p=0.0156), week 6 
(mean = -2.12 vs baseline, p<0.0001) and week 12 (mean=-2.39 vs. 
baseline, p< 0.0001), resulting in a high significant global treatment 
effect (F-test: p<0.0001).   
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Not only DAS28, but also other variables, such as tender or swollen joint 
counts can be used as continuous outcome measures, evaluated at 
different time points. However, as shown in Figure 1, DAS28 can 
discriminate more efficiently the two treatment groups than each of its 4 
components alone (less overlap of error bars) or the 66/68 joint counts. 
This also suggests that the reduction of the number of evaluable joints by 
the use of a 28 joint count is not a draw-back for the efficacy of the 
DAS28.  
In conclusion, we evaluated different RA related outcome measures and 
statistical methods to measure effects of therapy in PsA patients. We 
showed that the different response scores are equally efficient. Also, the 
DAS28, as a measure of absolute disease activity, can be used as a 
powerful tool to evaluate effects of therapy in PsA patients.  
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TABLES AND FIGURES 
 
Table 1: Patients’ baseline characteristics and comparison of the different 
outcome measures evaluating the effects of therapy. 
 Placebo Infliximab Difference Between groups 
Baseline characteristics    
Age (years) $ 47(39-63) 48(30-65) NS 
male/female* 4/5 5/4 NS 
Disease duration (years) $ 5(3-26) 5(1-18) NS 
Patient global assessment VAS$ 47(24-97) 66(42-84) NS 
Physician global assessment VAS$ 65(51-77) 65(60-85) NS 
66 swollen joint count$ 8 (1-17) 9(3-14) NS 
28 swollen joint count$ 4 (1-7) 5 (1-9) NS 
28 tender joint count$ 5 (1-10) 4 (1-8) NS 
ESR (mm/first hour) $ 8 (4-43) 11 (1-26) NS 
CRP (mg/dl) $ 0.8 (0.27-1.51) 0.96 (0-2.41) NS 
DAS28 § 3.78 (1.16) 4.32(1.21) NS 
HLA-B27 positive/negative * 3/6 2/7 NS 
Effects of therapy    
mACR no/20/50/70 responders* 8/0/1/0 0/3/2/3 γ= 0.861 +/-0.142 p=0.002 A 
mACR 20 responders (no/yes)* 8/1 1/8 OR= 28 (CI:2.1-379) p=0.015 B 
No/moderate/good DAS28 response* 7/2/0 0/1/7 γ= 0.944 +/-0.067 p=0.001 A 
Moderate DAS28 respons (no/yes)* 7/2 0/8 OR= 28 (CI:2.1-379) p=0.015 B 
PsARC response : no-yes* 7/2 0/9 p=0.002 B 
Remaining DAS28 score at week 12$ 3.91(1.48) 2.06(0.84) p=0.0065 C 
Difference in DAS28 score between 
baseline and week 12$ 
+0.127(0.84) 
p=NS D 
-2.26(1.33) 
p=0.0009 D  
Area under the curve -0.95 -29.31 p=0.0056 E 
Legend:  
$ Values are the median (range), § Values are the mean (standard 
deviation), * Values are number of patients in each category 
Statistical methods : A: Exact Gamma statistic, B: Fisher Exact, C: t-test, 
D: paired sample t-test, E: Mann-Whitney test,  
Abbreviations: NS= not significant, VAS= visual analogue scale, ESR= 
erythrocyte sedimentation rate, CRP= c-reactive protein, CI= 95% 
confidence interval, γ= Gamma statistic [8], OR = odds ratio. 
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Figure 1: Plots of the DAS28 score and different single measures. 
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Legend:   
Panel A: Evolution of the DAS28 over time. Panel B-E: Evolution of the 
components of the DAS28 over time.   
Panel F-G: Evolution of 66 and 68 swollen en tender joint counts over 
time.  
Those plots show that there is more overlap of the error bars of the 
individual components and the 66 and 68 swollen joint counts than the 
DAS28. 
Abbreviations: Sqrt= squared root, ln= natural logarithm, VAS= visual 
analogue scale.  
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CHAPTER 11 
Prediction of dose intensification for Rheumatoid Arthritis patients under 
Infliximab treatment. 
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Vastesaeger, Anja Geldhof, Luc Boullart, Filip De Keyser 
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DISCUSSION 
 
1. 
CARD15 and ASCA in SpA and Crohn: explorative association studies 
 
2. 
ACPA and RF as diagnostic markers for RA: validation of its diagnostic 
value and construction of (diagnostic) prediction models 
 
3.  
Evaluation of different measures and composite indices as a measure of 
(insufficient) response to treatment in RA (and PsA) 
 
4.  
Optimalization of the statistical methods to construct prediction models 
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1 CARD15 and ASCA in SpA and Crohn: explorative association 
studies 
The first requirement of a new biomarker is that this marker should be 
associated with the disease or with a specific clinical subtype. Carriage of 
CARD15 polymorphisms has been associated with Crohn’s disease (CD). 
The CARD15 gene encodes for the intracellular NOD receptor and 
a change in function of this receptor might lead to disturbed early 
inflammatory monocyte response to microbial agents finally 
resulting in gut inflammation [Peeters 2006]. As CD and gut 
inflammation are related with SpA, we investigated whether the carriage 
of CARD15 polymorphisms is associated with specific SpA related 
symptoms such as arthritis, inflammatory low back pain or sacroiliitis 
(Chapter 1). We found an association between the carriage of CARD15 
mutations and the occurrence of sacroiliitis. This association was 
independent of different possible confounding factors including HLA-
B27.  
We investigated the opposite question in Chapter 2 by investigating SpA 
patients who had undergone a colonoscopy and found that SpA patients 
with chronic gut inflammation are more frequently positive for the CD 
associated CARD15 polymorphism.   
In Chapter 3, we report that CD patients who carry CARD15 
polymorphisms are more frequently positive for ASCA and have higher 
titres than patients carrying wild types. We observed also a gene dose 
effect: homozygotes or compound heterozygotes were more frequently 
ASCA positive than single heterozygotes, which are on their turn more 
frequently ASCA positive than wild types.  
In the worldwide research for new genes for complex diseases such as 
SpA and CD disease, genetic association studies, as performed in these 
first 3 Chapters, are a powerful tool to explore the relationship between 
genes and the occurrence and clinical presentation of diseases. However, 
such associations should be interpreted with caution. It has been 
demonstrated that many reported association studies cannot be replicated 
or corroborated. This non-reproducibility may have different causes that 
are reviewed in Table 2.1. Some of these problems can be illustrated by 
the non-reproducibility of the association between CARD15 and ASCA 
reported in different analyses of a British cohort of CD patients [Arnott 
2004, Walker 2004, Smith 2004].  In contrast to other, more recent 
studies that confirm the association between carriage of CARD15 
mutations and ASCA [Amnese 2005, Riis 2005], this association could 
not be found in this British cohort of which several reports are published 
[Arnott 2004, Walker 2004, Smith 2004]. The non-reproducibility of the 
association between CARD15 and ASCA in this British cohort might be 
explained by a combination of heterogeneity and lack of power. First, the 
prevalence of carriage of CARD15 mutations in the CD patients enrolled 
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in that British cohort is only 24%, which is significantly lower than the 
45.5% reported in our Belgian cohort. The low prevalence of carriage of 
CARD15 mutations in this cohort may lead on its turn to a decrease of 
power to detect a difference of ASCA titres between CARD15 carriers 
and wild type patients and resulting in the false conclusion that there is no 
association between carriage of CARD15 mutations and ASCA.  
The reasons why the association between carriage of CARD15 
polymorphisms and sacroiliitis in Crohn’s disease patients could not be 
replicated in a Belgian multicentre study are more difficult to unravel 
[Peeters 2006]. We first observed significantly different frequencies of 
sacroiliitis between centers. Secondly, differences in disease duration 
might explain that some patients, prone to develop sacroiliitis had not yet 
developed sacroiliitis. Also differences in association between CARD15 
and ileal disease between centers could be observed. Whether several of 
such confounding factors have caused this non-reproducibility or whether 
this non-reproducibility was caused due to random error remains 
uncertain. 
The clinical relevance of most reported genetic associations for diagnosis 
and prognosis is generally low. Also in our studies, the sensitivities and 
specificities of the presence of CARD15 genes for the prediction of 
sacroiliitis or chronic gut lesions were low. Many genes discovered in 
complex multigenetic disorders are associated with the disease with ORs 
between 1.1 and 1.5. Although this is too low for clinical decision-
making, such associations may be interesting from a pathological point of 
view [Ioannidis 2003]. Previous studies could not detect a significant 
association between carriage of CARD15 mutations and the susceptibility 
for SpA [Micelli-Richard 2002, D’Amato 2002, Ferreiros-Vidal 2003, 
van der Paardt 2003]. However, none of them was sufficiently powered to 
detect an OR of 1.5.  
Also in Crohn’s disease, the clinical relevance of CARD15 determination 
should be further established. Combinations of different serological tests 
have been explored to facilitate the diagnosis of Crohn’s disease. In such 
models, CARD15 determination may have only limited additional value 
to serological testing [Vermeire 2004] which can be, at least partially, 
explained by its association with ASCA, which is more easy and cheaper 
to determine. Although for the moment not useful for clinical decision 
making, the reported association studies may be important for further 
understanding SpA and Crohn’s disease and fine-tunning disease 
definitions and disease categories [Cardon 2001].  
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Table 2.1: Possible reasons for the non-reproducibility of genetic 
association studies. 
1) Statistical reasons 
a. Lack of power (false negativity):  
Large sample sizes are needed to detect a 
statistical significant association. It has been 
estimated that most genetic associations between 
a polymorphic locus and disease yield an odds 
ratio between 1.1 and 1.5, requesting samples 
sizes of more than 1000 patients. 
b. Multiple comparison (false positivity – type I error): 
The more hypotheses that are tested, the more 
chance there is on false positive findings 
c. Interaction 
A disease may be caused by the interaction 
between two genes or by interaction between 
genes and the environment. Thus, when 
interaction terms are not investigated, the 
existence of a true association in a subgroup of 
patients can be overlooked. 
d. Stratification 
Population stratification occurs when genetic 
variants are studied in a mixture of genetically 
distinct populations. If the disease is more 
common in a particular ethnic group, any 
polymorphism that is associated with that ethnic 
group will appear to be associated with the 
disease. 
e. Random error 
When the random error is controlled at 5% 
(p<0.05), there is still a possibility of 5% that the 
study can not be replicated.    
2) Publication bias 
It may happen that subsequent studies cannot replicate 
both initial positive or negative results. However, 
positive findings are more likely to be published and 
attract more subsequent studies. 
3) Heterogeneity 
a. Locus and allelic heterogeneity 
This is a form of genetic expression in which 
distinct mutant alleles at the same or at different 
loci lead to the same disease phenotype. 
b. Definition of the phenotype 
Differences in the definition of the phenotype 
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may attribute patients to different phenotypes, 
resulting in differences in association. 
c. Definition of the genotype 
Differences in analysis on allele level or on 
haplotype level may cause differences in 
association. 
4) Linkage disequilibrium  
This is the tendency that genes and other genetic markers 
located close to each other on the same chromosome 
inherit together.  
Refs: Salanti 2005, Ioannidis 2001, Cardon 2001, Cardon 2003, Colhoun 
2003, Gambaro 2000, Thomas 2004,  Cappelleri 1996. 
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2 ACPA and RF as diagnostic markers for RA: validation of their 
diagnostic value and construction of a (diagnostic) prediction model. 
After a marker proved to be associated with a disease, it is important to 
explore its diagnostic properties (including sensitivity and specificity) in 
diverse subpopulations. Different studies in RA patients and different 
control populations previously highlighted the excellent diagnostic 
properties of ACPA testing [Chapter 4, Schellekens 2000, Pinheiro 2003, 
Union 2002, Noguiera 2002]. In the next steps, it may be important to 
translate the results of sensitivities and specificities to the single patient in 
daily clinical practice. We first addressed the question whether ACPA 
may occur in PsA patients. We and others demonstrated that ACPA 
positivity can be seen in 5.6% to 15.6% of PsA patients [Chapter 5, 
Alenius 2005, Bogliolo 2005, Korendowych 2005]. Selected false 
positivity of ACPA testing has also been reported in patients with 
systemic lupus erythematosus (SLE) [Hoffman 2005, Mediwake 2001] 
and primary Sjögren’s syndrome [Gottenberg 2005, Tobon 2005]. Also, 
PsA and SLE patients with a positive ACPA test have a higher risk to 
develop more erosive disease [Korendowych 2005, Boglioglio 2005, 
Inanc 2006].  
During the process of the development of a new marker, it may occur that 
different methods are developed to test the same or a similar marker. We 
evaluated the diagnostic properties and the agreement between the 
different ACPA tests in Chapter 7. Although anti-CCP and AhFibA 
assays had similar sensitivities and specificities, the 
correlation/agreement between those different tests was only moderate. 
This impaired agreement was especially observed in the non-RA patients 
in whom a (false) positive ACPA test could be confirmed in only 3 of 11 
cases. Some biological explanations for this observation have been 
formulated in the same chapter. Specific problems with the moderate 
agreement between the mentioned ACPA assays may occur when 
prediction models are described. Generalising prediction models becomes 
more difficult when the agreement between tests is only moderate.  
Another way to translate sensitivities and specificities to the single 
patient in daily clinical practice is by calculating the positive predictive 
value of a test. However, in the introduction and in Chapter 6, we 
indicated that thinking in probabilities for disease may be better. 
Thinking in probabilities, modelled by logistic regression, is especially 
helpful when different diagnostic markers are combined in order to select 
the most appropriate combination of different diagnostic tests. We thus 
showed that HLA-SE testing is not useful in combination with ACPA 
testing. This can be explained by the high association between ACPA and 
HLA-SE in patients with established disease. We previously described 
another association between a genetic marker and a serological marker 
(Chapter 3). Different associations between genetic alterations and the 
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occurrence of (auto) antibodies have been described in many other 
diseases. In Type 1 diabetes, different disease associated antibodies are 
associated with susceptible HLA class II alleles defining different 
subtypes of Type 1 diabetes [Delamaire 1995, Sabbah 1999, Hermann 
2004, Gorus 1994]. Carriage of other HLA class II alleles have been 
associated with a specific antibody response to nuclear antigens, in 
particular anti-SSA/Ro52, both in primary Sjögren’s syndrome and lupus 
[Smolens 1987, Gottenberg 2003, Tsao 2002]. Other nuclear antibodies 
(anti-SSB/La), associated with HLA class II genes have also been linked 
with carriage of polymorphisms in the genes for transforming growth 
factor-β and tumor necrosis factor-α in patients with primary Sjögren’s 
syndrome [Gottenberg 2005]. Different hypotheses can be generated to 
explain how the carriage of different HLA types or different gene 
polymorphism on the promoters of cytokines may influence antibody 
responses [Lard 2003, Gottenberg 2003]. 
By combining the knowledge of the genetic susceptibility of carriers of 
HLA-DQ2 or HLA-DQ8 genes with the discovery of the almost 
pathognomonic autoantibodies against tissue transglutaminase, important 
progress has been made in the understanding of the pathogenesis of celiac 
disease [Mowat 2003, Reif 2004]. 
Similarly, different hypotheses for the pathogenesis of RA have been 
generated. The carriage of the HLA-SE leading to genetic susceptibility 
for RA generated the hypothesis that specific proteins or peptides, 
relevant for the pathogenesis of RA, might have a high affinity for the 
HLA-SE. This focused some investigators on the human cartilage gp-39, 
which is a protein that can be retrieved in RA cartilage and synovium 
[Baeten 2004]. Citrullination of peptides might lead to a better interaction 
with the HLA-SE [Hill 2003] however citrullination is not mandtory for 
binding of fibrinogen to HLA-DR [Auger 2005]. 
Serological testing cannot only be useful for establishing a diagnosis, but 
also for estimating a prognosis. Different models to predict erosions have 
previously been suggested [Visser 2002, Nell 2005, Vencovsky 2003, 
Genevay 2002]. 
In some diseases, it has been proven that antibodies may occur before 
clinical symptoms are present, and thus can be used for early screening 
strategies and early therapeutic intervention. Such preventive therapeutic 
strategies are especially investigated for type I diabetes [Wilson 2001]. 
Similarly, it has been proposed to perform first a genetic testing and, if 
positive, to perform subsequent serial autoantibody testing in patients 
with a high risk to develop celiac disease [Liu 2005]. Whether such 
testing strategies might be useful for RA before any symptom has 
occurred remains to be proven [Berglin 2004].  
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3. Evaluation of different measures and composite indices as a 
measure of (insufficient) response to treatment in chronic arthritis. 
In the Chapters 8-10, we focused on clinical measures and composite 
indices to evaluate RA disease activity. An important issue in this context 
is the question how results from clinical trials can be best translated to 
daily clinical practice.  
The aim of a therapeutic strategy is to ameliorate the outcome. For RA, 
the therapy should target to reduce the symptoms of pain and swelling, to 
conserve the function and to avoid joint-destruction. In clinical trials 
however, “surrogate outcomes” are frequently defined [Piantadosi 1997]. 
Such surrogate outcomes are only valid if they proxy an outcome, in this 
case less destructive disease [Tugwell 1993]. For rheumatic diseases, the 
special study group OMERACT, has defined three conditions wchich 
should be fulfilled by an appropriate outcome measure: it should be true, 
discriminative and feasible [Boers 1998]. An outcome measure is true, 
when it measures what it intends to measure. Discriminative means that 
an outcome measure should also be able to discriminate between the 
situations of interest. This is important for classification or for the 
determination of a prognosis. Finally, an outcome measure should be 
feasible which means that the measure should be applied easily and 
should be easy to interpret [Boers 1998].   
Statistical methods can be used to evaluate the discriminative properties 
of an outcome measure [Verhoeven 2000]. In Chapter 8, we defined the 
best standard for insufficient response to therapy as the physician’s 
decision to give a dose increase of Infliximab therapy. In this study, we 
aimed to find the most appropriate single measure or composite index 
that could discriminate this decision. Therefore, we ranked all possible 
outcome measures based on their AUC of ROC curve analyses and the 
sensitivities at the 98% specificity level. This ranking showed that the 
DAS28, reflecting the disease activity at the moment of the decision, had 
the highest ranking. In the next steps, we tried to find a better model by 
combining different outcome measures, but we found that the final model 
had only slightly better discriminating properties compared to the 
DAS28. Finally, we recalculated the scores and coefficients by means of 
discriminant analysis and found similar scores and coefficients as the 
DAS28. We thus validated for the first time the DAS28 in a cohort of RA 
patients under biological therapy, more than 10 years after the initial 
development of the DAS. Differences between the initial study and the 
present study are highlighted in Table 1.3. 
The evaluation of DAS is useful to evaluate the disease activity of RA 
patients in placebo-controlled trials [Fuchs 1993, Landewé 2002], and we 
suggested that it may also be used to evaluate the effect of therapy in PsA 
patients [Chapter 10]. The repeated measurement of DAS28 is a valid 
method to evaluate effects of therapy by applying area under the curve or 
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mixed models analysis. Interestingly, although PsA patients may show 
less swollen and tender joint counts than RA patients, we showed that this 
seems not to matter for the use of the DAS28. This can be at least 
partially explained by the squared root transformation applied to the SJC 
and TJC which leads to the phenomenon that a change in the low ranges 
has a higher impact on the DAS28 than the same change in the higher 
joint count ranges. 
The ideal outcome measure should not only be applicable in clinical 
trials, but also in daily clinical practice so that results from trials can be 
easily translated into concepts for daily clinical practice. There is rising 
evidence that the DAS28 can be used both in clinical trials and in daily 
clinical practice. The response scores “ACR response” and “DAS 
response” measure differences over time and are thus not suited to 
evaluated momentary disease activity [Fransen 2004]. Compared to DAS, 
simplified disease activity index (SDAI) and clinical disease activity 
index (CDAI) are not normally distributed, which is a drawback for some 
statistical methods [Van der Heijde 1993, Smolen 2003]. 
Tight monitoring of the DAS with subsequent therapy adjustments, leads 
to a global improvement of the disease activity, a better functional 
outcome and a lower radiological progression rate [Grigor 2004, Welsing 
2004, Landewé 2002, Gossec 2003, Drossaers-Bakkers 1999, Fansen 
2005]. 
In Chapter 9, we showed that the DAS28, measured at week 14 or week 
22 is a predictor of infliximab survival. If there is a remaining high 
disease activity at week 14 to 22 after start of infliximab, other 
therapeutic strategies should be considered. 
Although we showed in Chapters 8 and 9, that DAS28 is the best 
composite index to model the physician’s concept of disease activity, it is 
important to state that this is true on the population level, but that 
exceptions may occur on the individual level. This has been explored by 
different authors. First, studies evaluating remission criteria showed that 
tender joints and swollen joints may be present in the case that the 
classical DAS28 remission criterion (DAS28 < 2.6) [Prevoo 1996] is 
fulfilled, suggesting that some single patients with a low DAS28 may in 
fact still have some disease activity [Van der Heijde 2005, Mäkinen 
2005]. Second, it may be important to keep in mind that toe joints are not 
evaluated by the DAS28. Also, there is no perfect fit between DAS28 and 
the physician’s appreciation of disease activity VAS [Wolfe 2005, 
Chapter 8]. Taking into account the reasons for DAS28 to over or 
underestimate disease activity, DAS28 may be a useful tool to evaluate 
disease activity in RA patients in daily clinical practice. Thus, using 
DAS28 may be helpful so that results and treatment goals achieved in 
randomised clinical trials and studies of treatment strategies can be easily 
translated into daily clinical practice treatment goals.  
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Table 3: Comparison of the original construction of the DAS with the 
present validation study. 
Initial studies*° Present study§ 
113*/227° patients 511 patients 
Recent onset RA (< 1 year) Long-standing disease 
DMARD-therapy Infliximab (+ MTX)-therapy 
Different time points 1 time point (week 22) 
1 centre (6 rheumatologists) Different centres 
Scored by research nurses Scored by a physician 
 
* Van der Heijde 1993: DAS44 
° Prevoo 1995: DAS28 
§ Chapter 8: DAS28 
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4. Optimalization of statistical methods to construct prediction 
models 
In Chapter 11 we evaluated the use of more sophisticated classification 
methods in multidimensional classification issues and compared them 
with discriminant analysis or logistic regression. We showed that, when a 
limited number of variables are considered, discriminant analysis and 
logistic regression perform rather well, but that their performance gets 
worse when more dimensional datasets are used requiring a feature 
selection method. In cases where no feature selection can be performed, 
more complex methods such as support vector machines (SVM) and 
multilayered perceptrons (MLP) seem to be more relevant. This is 
congruent with another study that compared MLP with logistic 
regression. Similar performance of MLP and logistic regression was 
observed for dichotomous outcomes. However, for ordinal outcomes, 
MLP performed better [Ergün 2004]. 
Those studies suggest that for simple classification problems, logistic 
regression and discriminant analysis perform rather well. Only for more 
dimensional datasets, or non-linear data, more complex methods should 
be considered. All methods however seem to suffer from the so-called 
“curse of multidimensionality” [Bellman 1957]. This means that when 
more variables are available, classification methods perform less well. 
Adding more variables for classification not only adds information, but 
also noise which may impair the classification task. This problem 
becomes more and more relevant with the introduction of new assays in 
which multiple markers can be tested simultaneously by means of micro-
bead assays [Fulton 1997] or micro-array analysis [Southern 2001]. In 
Chapter 11 we showed that, when no feature selection method can be 
used, among the evaluated methods, SVM seem to be the best choice. 
Which feature selection method should be used, remains to be further 
established. We used a combination of formal methods such as ROC 
curve analysis and logistic regression with domain knowledge [Chapter 8, 
11]. However, more difficulties will arise in more complex problems 
generated by micro-array analysis: sample sizes are generally smaller and 
more variables are available. 
To conclude, high dimensional datasets remain a challenge for statistical 
analysis. New methods are under investigation for feature selection and 
classification. 
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SUMMARY 
 
This work aims to illustrate how single biomarkers and standardized 
clinical measures can be used in the daily clinical practice 
rheumatologist’s decision making and how different markers and 
measures can be combined into prediction models and composite indices. 
 
The first part focuses on association studies. First, a potential biomarker 
(or clinical measure) should be associated with the disease. Association 
studies provide a powerful tool to discover new markers but have the 
major draw-back that replication may be difficult. Three association 
studies of carriage of Crohn’s disease associated CARD15 
polymorphisms are shown. We first investigated the association between 
carriage of CARD15 polymorphisms and SpA related symptoms in 
Crohn’s disease. Inversely, the association between gut inflammation in 
SpA and carriage of CARD15 polymorphisms was explored. These 
associations may suggest a genetic link between gut and joint 
inflammation. Also, an association between carriage of CARD15 
polymorphisms and anti-Saccharomyces cerevisiae antibodies in Crohn’s 
disease patients is demonstrated. Although the discovery of CARD15 
polymorphisms may be important for the understanding of Crohn’s 
disease and Spondyloarthropathy, their diagnostic value is weak and 
therefore, CARD15 determination is not recommended for daily clinical 
practice. 
 
The diagnostic properties of a test are explored into more detail in part 2, 
illustrated by the RF and ACPA determination in RA. ACPA is a very 
specific test for RA, but the specificity of this test may differ between 
study populations. A higher ACPA false-positivity rate than expected (in 
a random control population) can be observed in PsA patients. 
Combinations of ACPA, RF and HLA-SE testing are explored by 
different (predicted) probabilities plots, based on logistic regression. 
They demonstrate that combined ACPA and continuous RF-testing is the 
most relevant combination. Finally, different ACPA tests are compared 
side-by-side showing that different ACPA tests may have similar 
diagnostic properties, but that disagreement between tests may occur. 
 
In part 3, different single clinical measures and composite indices to 
measure response to treatment in RA (and PsA) are evaluated. 511 RA 
patients treated with infliximab are investigated. After a loading regimen 
at week 0, 2, 6 and 14, the treating rheumatologist could decide to give a 
dose increase at week 22. This decision to give a dose increase can be 
considered as a measure of insufficient response and could be best 
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modeled by the DAS28 at the moment of decision. The same patients 
were followed over 4 years and also DAS28, measured at week 14 or 
week 22, could best predict 4-year attrition to therapy. DAS28 as a 
continuous measure of disease activity in RA patients can be used in 
clinical trials and in daily clinical practice to make treatment decisions. 
Also, measuring of the DAS28 score in PsA may be useful to evaluate 
effects of therapy in placebo-controlled trials.   
 
In the last part, different methods to construct prediction models are 
evaluated. Discriminant analysis and logistic regression may be less 
performing in real life datasets with missing values and high 
dimensionality. In such cases, computer intensive methods – such as 
support vector machines and multilayerd perceptrons - may be useful. 
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SAMENVATTING 
 
In deze thesis wordt geïllustreerd hoe merkers uit bloedanalyses en 
gestandaardiseerde klinische metingen de reumatoloog kunnen helpen om 
beslissingen te nemen in de dagelijkse klinische praktijk en hoe 
verschillende merkers en metingen samengevoegd kunnen worden in 
modellen en indexen. 
 
Het eerste deel van dit werk handelt over associatie studies. Een 
biomerker (of klinische meting) moet geassocieerd zijn met de ziekte. 
Associatie studies kunnen gemakkelijk nieuwe merkers aan het licht 
brengen, maar hebben het grote nadeel dat het vaak moeilijk is om de 
resultaten te reproduceren. Drie associatie studies worden getoond met 
betrekking tot polymorphismen in het CARD15 gen, die frequenter 
voorkomen bij patiënten met de ziekte van Crohn. De associatie tussen 
het dragen van een CARD15 polymorphisme en het voorkomen van SpA-
gerelateerde symptomen in Crohn patiënten wordt nagegaan. Anderzijds 
wordt ook de relatie tussen het dragen van een CARD15 polymorphisme 
en darm ontsteking in SpA nagegaan. Deze associaties suggereren een 
genetische link tussen darm en gewricht. Verder wordt ook aangetoond 
dat patiënten met de ziekte van Crohn die een CARD15 polymorphisme 
dragen frequenter antistoffen aanmaken tegen Saccharomyces cerevisiae 
(of bakkersgist). Hoewel deze associatie studies ons mogelijk meer leren 
over het verband tussen de ziekte van Crohn en SpA, heeft het testen op 
de aanwezigheid van CARD15 polymorphismen weinig diagnostische 
waarde en wordt dit niet aanbevolen voor de dagelijkse praktijk.  
 
In het tweede deel van dit werk wordt nagegaan aan welke eigenschappen 
een diagnostische test moet voldoen aan de hand van 2 serologische tests 
voor reumatoïde artritis (RA): reumafactor (RF) en de antistoffen tegen 
gecitrullineerde eiwitten (ACPA). Dergelijke ACPA tests zijn zeer 
specifiek voor RA maar de specificiteit kan verschillen tussen 
studiepopulaties. Zo komt een (vals) positieve ACPA test bij patiënten 
met psoriasis artritis frequenter voor dan kan verwacht worden, gegeven 
door de specificiteit van de test in willekeurige controle populaties.  
Verschillende combinaties van ACPA, RF en de HLA-SE worden 
bestudeerd aan de hand van kansgrafieken die berekend werden met 
behulp van logistische regressie. Hiermee kan aangetoond worden dat een 
combinatie van een continue reumafactor test met een ACPA test de beste 
testbatterij is. Tot slot worden een aantal ACPA tests direct met elkaar 
vergeleken waarbij aangetoond wordt dat deze tests vergelijkbare 
diagnostische kenmerken hebben, maar dat discrepante resultaten kunnen 
voorkomen. 
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In deel 3 worden verschillende gestandaardiseerde klinische metingen en 
indexen bestudeerd die gebruikt worden om het effect van een 
behandeling te meten bij patiënten met reumatoïde (of psoriasis) artritis. 
Hiervoor worden 511 RA patiënten bestudeerd die behandeld werden met 
inflximab. Nadat de patiënten een oplaaddosis hadden gekregen op week 
0, 2, 6 en 14 kon de arts op week 22 beslissen om een dosisverhoging te 
geven. Deze beslissing om een dosisverhoging te geven kan beschouwd 
worden als een maat van onvoldoende respons en kan het best 
gemodelleerd worden door het meten van de DAS28 op het moment van 
de beslissing zelf. Dezelfde patiënten werden ook over 4 jaar gevolgd 
waarbij aangetoond wordt dat de ziekte activiteit, gemeten op week 14 of 
week 22 met behulp van de DAS28 het best vroegtijdig kan voorspellen 
of patiënten ook nog na 4 jaar onder behandeling blijven. DAS28 als een 
continue maat van ziekteactiviteit bij RA patiënten kan gebruikt worden 
in klinische studies en in de dagelijkse kliinische praktijk om beslissingen 
te maken over therapie. Verder wordt ook aangetoond dat het meten van 
de DAS28 ook kan gebruikt worden om het effect van therapie te 
evalueren bij patiënten met psoriasis artritis. 
 
In het laatste deel worden een aantal methoden geëvalueerd die gebruikt 
worden om voorspellingsmodellen en indexen te maken. Discriminant 
analyse en logistische regressie zijn vaak minder performant in datasets 
met ontbrekende waarden en hoog-dimensionele datasets. In dergellijke 
gevallen kan het nuttig zijn om computer intensieve methoden te 
gebruiken zoals support vector machines en multilayered perceptrons.  
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